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Abstract
It has been well established that smoking is the leading avoidable cause of premature morbidity and
mortality in the United States and abroad. Smoking is attributable to over 400,000 annual deaths, and
$193 billion in healthcare costs and lost productivity. Despite the apparent dangers and tremendous costs
of tobacco use and dependence, smokers find difficulty quitting. Recently, stepped care has been
proposed as a viable intensive approach for achieving long-term cessation. This research sought to
evaluate cost-effectiveness of stepped care in a diverse population of smokers and analyze future health
outcomes of smoking cessation.
Cost-effectiveness analysis was conducted from an institutional perspective alongside an NIH-funded
multi-site study, “Long-term Smoking Cessation Using Prescription Step Care” (STEP), which compared
stepped care to a repeat care intervention. The outcome of interest was incremental cost per quit
achieved by stepped care. Secondly, long-term cost-effectiveness of successful smoking cessation was
analyzed using a societal perspective. A microsimulation model was developed to predict changes in
morbidity and mortality over the lifetime for four smoking-related diseases (ischemic heart disease,
cerebrovascular disease, lung cancer, and emphysema) due to successful cessation. Here, the outcome
of interest was incremental cost per quality-adjusted life year due to successful cessation. Lastly,
sensitivity analyses were conducted to gauge robustness of estimates.
In the STEP study, costs for stepped versus repeat care were $875.09 and $422.26, respectively. Pointprevalence abstinence was validated among 20.5% (versus 22.5%) of stepped care patients; continuous
abstinence was achieved by 11.9% (versus 14.3%) of stepped care patients. Stepped care was dominated
by repeat care, being more costly but less effective. Stepped care produced a favorable incremental costeffectiveness ratio only among women achieving continuous abstinence in the Mayo sample. All other
scenarios favored repeat care. When future outcomes of cessation were analyzed, average costs in
original versus amended analyses were $49,025 and $48,956, respectively; QALYS gained were 8.62 and
8.6, for the aforementioned analyses. Successful cessation yielded incremental cost-effectiveness of
$3,450 per QALY. In sensitivity analysis, incremental cost-effectiveness varied from cost-saving to
$13,700 per QALY.
Stepped care was not cost-effective relative to repeat intervention. Quitting at the UTHSC site and among
ethnic minorities was low, despite better rates of participation. Higher depression scores may have
attributed to these results. Success of repeat care in STEP affirms findings of two recent studies.
However, long-term cessation did prove highly cost-effective. Smoking cessation interventions continue
to be extremely cost-effective and provide sizable returns on investment to employers and payers alike;
enhanced coverage of smoking cessation treatments and programs will likely increase quit attempts and
ultimately, cessation.
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ABSTRACT
It has been well established that smoking is the leading avoidable cause of
premature morbidity and mortality in the United States and abroad. Smoking is
attributable to over 400,000 annual deaths, and $193 billion in healthcare costs and lost
productivity. Despite the apparent dangers and tremendous costs of tobacco use and
dependence, smokers find difficulty quitting. Recently, stepped care has been proposed as
a viable intensive approach for achieving long-term cessation. This research sought to
evaluate cost-effectiveness of stepped care in a diverse population of smokers and
analyze future health outcomes of smoking cessation.
Cost-effectiveness analysis was conducted from an institutional perspective
alongside an NIH-funded multi-site study, “Long-term Smoking Cessation Using
Prescription Step Care” (STEP), which compared stepped care to a repeat care
intervention. The outcome of interest was incremental cost per quit achieved by stepped
care. Secondly, long-term cost-effectiveness of successful smoking cessation was
analyzed using a societal perspective. A microsimulation model was developed to predict
changes in morbidity and mortality over the lifetime for four smoking-related diseases
(ischemic heart disease, cerebrovascular disease, lung cancer, and emphysema) due to
successful cessation. Here, the outcome of interest was incremental cost per qualityadjusted life year due to successful cessation. Lastly, sensitivity analyses were conducted
to gauge robustness of estimates.
In the STEP study, costs for stepped versus repeat care were $875.09 and
$422.26, respectively. Point-prevalence abstinence was validated among 20.5% (versus
22.5%) of stepped care patients; continuous abstinence was achieved by 11.9% (versus
14.3%) of stepped care patients. Stepped care was dominated by repeat care, being more
costly but less effective. Stepped care produced a favorable incremental costeffectiveness ratio only among women achieving continuous abstinence in the Mayo
sample. All other scenarios favored repeat care. When future outcomes of cessation were
analyzed, average costs in original versus amended analyses were $49,025 and $48,956,
respectively; QALYS gained were 8.62 and 8.6, for the aforementioned analyses.
Successful cessation yielded incremental cost-effectiveness of $3,450 per QALY. In
sensitivity analysis, incremental cost-effectiveness varied from cost-saving to $13,700
per QALY.
Stepped care was not cost-effective relative to repeat intervention. Quitting at the
UTHSC site and among ethnic minorities was low, despite better rates of participation.
Higher depression scores may have attributed to these results. Success of repeat care in
STEP affirms findings of two recent studies. However, long-term cessation did prove
highly cost-effective. Smoking cessation interventions continue to be extremely costeffective and provide sizable returns on investment to employers and payers alike;
enhanced coverage of smoking cessation treatments and programs will likely increase
quit attempts and ultimately, cessation.
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CHAPTER 1: INTRODUCTION
Overview
Smoking remains the leading cause of premature death and disability in the
United States. According to latest estimates, nearly one in five (19.8%) Americans
smokes. Smoking claims over 438,000 lives each year, and contributes $40 billion in
annual healthcare expenditures.1 Prevalence of smoking among adults stalled between
2004 and 2006, following a seven year decline; 2007 estimates indicate a significant
decrease in prevalence compared to the previous period. Despite efforts to curtail
adolescent initiation and current smoking, declines in smoking among youth between
1997 and 2003 have also stalled. In the United States, smoking prevalence is highest
among youth and young adult groups, signaling cause for concern. Outside the United
States, the toll of smoking on health is equally high. The World Health Organization
(WHO) estimates that global tobacco use results in 5.4 million annual deaths—one every
six seconds. Unless urgent action is taken, WHO expects that smoking will claim 1
billion lives by the end of the 21st century.2
Determinants of Smoking Patterns
Most smokers initiate habits in adolescence or early adulthood. Several factors,
both positive and negative, influence one’s decision to smoke. Figure 1-1, taken from the
2000 Surgeon General’s Report, outlines several factors (protobacco and antitobacco)
which may promote or deter one’s decision to initiate.3 For example, widespread social
and community norms which support tobacco use, coupled with peer pressure, strategic
marketing and placement of tobacco products in youth and community outlets, in the
absence of antitobacco efforts, will negatively influence adolescents’ perceptions about
smoking. Such factors support increased exposure to tobacco, which can lead to uptake.
Conversely, implementation of educational initiatives, creation of nonsmoking social
norms, and restrictions on tobacco marketing and product availability can delay or deter
adolescent initiation. Likewise, these factors influence decisions for continued smoking,
quitting, and relapse.
Psychosocial factors strongly influence predisposition to smoking. A number of
previous reports have revealed educational attainment as a strong sociodemographic
predictor of smoking patterns.4-7 This correlation continues to be supported in recent
literature, including new results from Meara and colleagues.8 Their analysis of changes in
mortality and life expectancy from 1981-2000 concluded that education level is a
mediator of life expectancy. Better educated individuals experienced a half-year increase
from the 1980s to 1990s, and a 1.6 year increase from 1990-2000, while the less educated
saw no changes during those periods. Moreover, the researchers found much of the
mortality gap to be attributed to smoking related illnesses—namely lung cancer and
chronic obstructive pulmonary disorder. Recent trends in quitting have paralleled those
related to uptake and current smoking. Often, groups that exhibit the greatest likelihood
of smoking behaviors are the least likely quitters.

1

Figure 1-1. Factors Influencing the Decision to Smoke
Source: U.S. Department of Health and Human Services. Reducing tobacco use : a
Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human
Services, Public Health Service, Office of the Surgeon General; 2000: p.7.3
Personal Health Consequences
Smoking harms nearly every organ of the body, attributing to heart disease, stroke,
certain cancers, pregnancy complications, and respiratory illnesses. Moreover, annual
tobacco-related deaths surpass those caused by human immunodeficiency virus (HIV),
illegal drug use, alcohol use, motor vehicle injuries, suicides, and murders combined.9
Unfortunately, smokers ignore the risks associated with tobacco use, as tobacco-related
disease may not surface for decades. Recent estimates reveal that premature death due to
smoking takes, on average, 12 years of life.10 The Centers for Disease Control and
Prevention reports that smokers are 2 to 4 times more likely to develop coronary heart
disease than nonsmokers; coronary heart disease is the leading cause of death in the
United States. Smokers also double their risk for stroke and are 10 times more likely to
develop peripheral vascular disease, due to impaired circulation.11 Nearly all lung cancer
deaths are attributable to smoking; other tobacco-related cancers include the bladder, oral
cavity, pharynx, larynx, esophagus, cervix, kidney, lung, pancreas, and stomach. AfricanAmerican men have the highest rates of cancer related to smoking. Negative reproductive
outcomes, including infertility, stillbirth, low birth weight delivery, and sudden infant
death syndrome (SIDS) are typically attributable to prenatal smoking.11 Lastly, smoking
can lead to asthma diagnosis and exacerbations, upper and lower respiratory illnesses and
infections, and in most cases, emphysema.11
Personal consequences of tobacco use, though delayed, are quite costly. In the last
few decades, several estimates of personal costs of smoking have been published in the
literature. One such study, conducted by Sloan et al., used available national data to
estimate lifetime private and social costs attributable to smoking.12 They calculated a
lifetime cost of $86,000 for a 24-year old woman; the cost increased to $183,000 for a
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male the same age. If these costs were considered in cigarette pricing, the price per pack
would be valued at $33. This accounted for both the cost of the product and the costs of
resultant ill health. Viscusi and Hersch, in 2007, estimated personal mortality costs to
smokers to be much higher than previous estimates, $222/pack for men and $94/pack for
women.13 The differences lie in valuation methods. Sloan and others presume that loss of
life due to smoking occurs at the end of life; these life-years supposedly have identical
values that are discounted to the present to represent mortality costs. Viscusi and Hersch
maintain that the “present value of the mortality cost of smoking is the discounted value
of the incremental probability of death at different ages for smokers relative to otherwise
comparable nonsmokers.”
Societal Consequences
Consequences of smoking extend beyond the individual; there is sufficient
evidence to confirm that nonsmokers experience negative health effects from exposure to
environmental tobacco smoke. 2, 14, 15 Passive smoking occurs when exhaled or ambient
smoke from a cigarette (or related product) is inhaled by others. The U.S. Centers for
Disease Control and Prevention estimates that 60% of Americans show biological
evidence of second-hand smoke exposure, and that second-hand smoke causes 35,000
deaths from coronary heart disease and 3,000 deaths from lung cancer among
nonsmokers each year.
Children are typically most vulnerable to environmental tobacco smoke exposure.
Etzel and others report that approximately 42% of children 2 months to 11 years of age
live in a home with at least 1 smoker and an estimated 8.7 to 12.4 million US children
younger than 5 years are exposed to cigarette smoke at home.16, 17 These exposures place
children at risk for asthma diagnosis and complications. Gilliland et al. and DiFranza et
al. affirm the effects of prenatal and maternal smoke exposure on developmental lung
defects, wheezing, and bronchial complications in children.18, 19 Additional research
affirms that prenatal smoke exposure (PSE) explains above asthma-related and other
health outcomes.18, 20-22
Adults exposed to environmental tobacco smoke face similar consequences. In
their recent report, Frieden and Blakeman found environmental tobacco exposure to be
associated with 25% higher risk for chronic respiratory disease, 40-60% higher risk for
developing asthma, and 50-100% higher risk for acute respiratory illnesses among
adults.23 These effects take a detrimental toll on the labor force. In the United States, the
Environmental Protection Agency estimates that second-hand smoke accounts for nearly
3,000 annual lung cancer deaths among non-smokers in the country, though the
methodology used to derive these estimates has been contested.24 Even abroad, the
International Labor Organization estimates that at least 200,000 employees die annually
due to exposure to smoke at work. In recent years, employers have responded by
mandating smoke-free workplaces; these and other clean air acts should greatly reduce
this number.25-28
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Enstrom and Kabat have challenged these observations, purporting that health
effects of secondhand smoke are exaggerated.29 In their 39-year study of environmental
tobacco smoke exposure and related mortality among nonsmoking Californians, they
found no significant evidence of a causal relationship between smoke exposure and
tobacco related mortality. The authors argue that most epidemiologic studies show
positive, yet statistically insignificant associations between environmental smoke
exposure and coronary heart disease and lung cancer. Meta-analyses yield significant
summary statistics, only when these data are combined, which do not provide strong
enough evidence to establish causality. These challenges have likely gone unnoticed by
consumers, whose perceptions about risks of second-hand smoke are relatively strong.
Dr. Rick Blizzard, a consultant for Gallup Healthcare, captured Americans’ beliefs in a
2004 poll regarding perceived effects of second-hand smoke.30 Over half of all
respondents (54%) believed that second-hand smoke is “very harmful”. Specifically,
women, more than men, held this view (63% and 44%, respectively). Another 32% of
participants believed that second-hand smoke is “somewhat harmful”. Only 4% of all
participants viewed second-hand smoke as not at all harmful. Younger respondents
(under 50) were more likely to view second-hand smoke as harmful as compared to older
respondents. These results may be due to enhanced efforts across the country to raise
awareness about second-hand smoke and its consequences.
The costs of smoking to society continue to grow drastically as more smokers live
with tobacco-related illnesses. These rising costs have fueled greater efforts across the
United States to promote smoking cessation. Costs of smoking are borne by employers,
managed care companies, spouses and families, as well as the larger community. Thus,
costs such as medical care (beyond the individual’s share), productivity, absenteeism,
spousal and familial morbidity, mortality and disability, transportation, and caregiver
time related to smoking must be considered. In 1998, Leonard Miller and his colleagues
at University of California estimated a total annual cost of care for tobacco-related
disease of $72.7 billion, using healthcare expenditure data from 1993.31 According to
their analysis, smoking accounted for nearly 12% of all healthcare expenditures. In
addition, they predicted that the actual cost of medical care for smoking-related diseases
would swell to $1.8 trillion over the next 25 years. Current estimates are nearly $96
billion for healthcare costs related to smoking. When productivity losses are included,
that estimate doubles to approximately $193 billion in annual tobacco-related losses.10
Barriers to Cessation
Nicotine addiction is pervasive among smokers and remains a key barrier to longterm smoking cessation .32 As the psychoactive drug element of tobacco products,
nicotine produces chemical dependence similar to that of heroin, cocaine, or alcohol.
Nearly three in four smokers report a desire to quit, but only a portion of them make
successful quit attempts. While onset of disease is a typical driver of cessation; data from
the 2006 National Health Insurance Study reveals significant age-adjusted smoking
prevalence among patients with any smoking-related chronic disease (36.9%). One in
five lung cancer patients and nearly half of those with emphysema in the sample were
current smokers.15 For these reasons, expert panel members of the Agency for Health
4

Care Policy and Research (AHCPR) Clinical Practice Guidelines for Treating Tobacco
Use and Dependence consider tobacco dependence a chronic disease requiring consistent,
sustained intervention.33 Patients often require multiple attempts, as nicotine withdrawal
symptoms can trigger relapse(s). Common withdrawal symptoms include nicotine
craving, irritability, anxiety, difficulty concentrating, restlessness, and increased
appetite.9 Weight gain relative to cessation is also a commonly cited concern among
female smokers, especially those who are overweight or obese.34, 35
Global Tobacco Control
Significant efforts to control tobacco use in the United States began around the
1960s, prompted by a landmark study of British doctors by Doll & Hill.36 Their 1954
study definitively linked smoking and lung cancer; previous studies on tobacco’s harmful
effects had been largely ignored. Researchers in the United States began similar
observations of smoking and its effects. In 1964, the first report of the Surgeon General
on smoking was released, initiating a unified movement in the U.S. toward reducing
tobacco use. Since then, various tobacco control strategies targeting current smokers have
been developed to promote cessation, namely pharmacotherapy and behavioral
counseling.
Pharmacotherapy
Pharmacological therapy was first introduced in 1985 and has been used
extensively over the past few decades to treat tobacco dependence. Pharmacological
agents for smoking cessation typically fall into two major categories: nicotine
replacement therapy (NRT) products and non-nicotine medications.9 Currently, seven
pharmacologic agents are approved in the United States as first-line for treating tobacco
dependence (5 NRT products and 2 non-nicotine products); these agents are highlighted
in the U.S. Guidelines for Treating Tobacco Use and Dependence: 2008 Update.33 A
large body of evidence exists which confirms the effectiveness and cost-effectiveness of
these agents, used alone or in combination, in achieving cessation.
Nicotine replacement therapies are designed to reduce withdrawal symptoms by
substituting for some of the nicotine absorbed from tobacco.2 NRT products are available
in various forms (patch, gum, inhaler, lozenge, nasal spray) and doses (0.5 mg-21 mg
depending on product type). Most are sold over-the-counter in local pharmacy, retail, and
grocery outlets; inhalers and nasal sprays require a prescription. Nicotine gums, lozenges,
and inhalers deliver nicotine orally, patches deliver nicotine through the skin, and sprays
deliver nicotine through the nasal cavity. Provision of a variety of NRT therapies
enhances smoking cessation efforts across a broad range of smokers. Preference studies
of nicotine replacement therapies reveal differential ratings of likability, perceived safety,
and ease of use.37 Patches rank high for convenience; they are adhered once daily and
provide sustained release of nicotine into the bloodstream. In contrast, smokeless tobacco
users may find nicotine gum more appealing; its administration is similar to chewing
tobacco, which (once activated) is placed between gum and cheek. Nicotine inhalers look
like plastic cigarettes; their administration mimics the hand-to-mouth movement of
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smoking. Nicotine nasal spray delivers nicotine to the bloodstream faster than any other
form, making it a great choice for smokers who need immediate relief from cravings.
Side effects of NRT are generally mild and well-tolerated; these vary by type.38 Most side
effects associated with NRT are minimized when used appropriately.
Besides nicotine replacement therapies, two non-nicotine medications, bupropion
and varenicline, can also be used first-line. Bupropion was approved in 1997 as a
smoking cessation aid, marketed as Zyban. It is also sold as the antidepressant Wellbutrin
in the United States. Bupropion is a relatively weak inhibitor of the neuronal uptake of
norepinephrine, serotonin, and dopamine, and does not inhibit monoamine oxidase. The
mechanism by which bupropion enhances the ability of patients to abstain from smoking
is unknown. However, it is presumed that this action is mediated by noradrenergic and/or
dopaminergic mechanisms.39 Varenicline, marketed as Chantix, is the first partial agonist
of the α4β2 neuronal nicotinic acetylcholine receptor to be developed.38 The efficacy of
varenicline in smoking cessation is believed to be the result of its activity at a sub-type of
the nicotinic receptor where its binding produces agonist activity, while simultaneously
preventing nicotine binding to α4β2 receptors.40 Both bupropion and varenicline are
associated with side effects. Bupropion users commonly report dry mouth and insomnia;
these are well tolerated and usually disappear after a few weeks. Hypertension has also
been reported. Common side effects of varenicline include nausea, insomnia, and
abnormal dreams. In addition, varenicline has become increasingly associated with
neuropsychiatric symptoms including changes in behavior, agitation, depressed mood,
suicidal ideation and suicidal behavior that may lead to discontinuation of therapy.41
These non-nicotine medications are available only by prescription.
Duration of pharmacotherapy ranges from a few weeks to six months and
treatment courses vary by product. In the Guidelines for Treating Tobacco Use and
Dependence, doses and recommendations for administration and duration are outlined for
all pharmacotherapies. Details for first-line agents are listed in Table 1-1. Wide
variations in duration and dosing indicate that treatment can be tailored to individual
preferences, dependence levels, and cessation history to enhance effectiveness. Assuming
daily cigarette consumption of one pack per day and treatment duration of six weeks
using nicotine patches, the typical smoker would begin with a daily dose of 21 mg for
four weeks, followed by two weeks at the 14 mg dose, and 7 mg for the final two weeks.
Most NRT treatment courses involve step-down dosing and depend on the cigarette
consumption of the smoker; however, dosing increases over the treatment period for nonnicotine medications. Patients interested in using pharmacotherapy to aid cessation
should consult their physician to determine which product(s) are most effective. In
addition, patient preferences and prior experiences with pharmacotherapy should be
considered when recommending a particular form for smoking cessation. Misuse of
nicotine replacement therapy is commonly cited in the literature, likely due to improper
administration, misconceptions of effectiveness, and safety concerns. Schneider and
others encourage sampling of smoking cessation therapies as a method for improving
treatment outcomes.37,42 When used appropriately, smokers can decrease their
dependence on nicotine and quit smoking permanently.
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Table 1-1. First-Line Pharmacotherapies for Smoking Cessation
Pharmacotherapy
Nicotine gum

Treatment
length
4-12 weeks

Nicotine patch

Varies3

Nicotine inhaler

Up to 6
months

Nicotine nasal spray 3-6 months

Nicotine lozenge

6-12 weeks

Bupropion

7-12 weeks;
Up to 6
months
3-6 months

Varenicline

Dosage
2 mg or 4 mg dose; 1 piece/
1-2 h; NMT 24 pieces/day1
Various doses; 21 mg
patch/day for 4 weeks, then
14 mg patch/day for 2
weeks, then 7 mg patch/day
for 2 weeks
4 mg; 6-16 cartridges/day,
then tapered dosing final 612 weeks4
0.5 mg/nostril (1-mg dose);
1-2 doses/h; at least 8
doses/day, NMT 40
doses/day
2 mg or 4 mg5; 1 lozenge/12 h for 6 weeks, then 1
lozenge/2-4 h for weeks 79, then 1 lozenge/4-8 h for
weeks 10-12
150 mg daily for three days;
then 150 mg twice daily

Cost
$48/box 2 mg,
$63/box 4 mg2
$37/box 7 mg,
$47/box 14
mg, $48/box
21 mg

0.5 mg/day for 3 days, then
0.5 mg twice daily for 4
days, then 1 mg twice daily

$131/month
(56 tablets)

$197/box (168
10mg
cartridges)
$49/bottle
(~100 doses)
$34/box 2 mg,
$38/box 4 mg
(72
lozenges/box)
$97/month (60
tablets)

1

Dose depends on cigarette consumption
2 mg box (100-170 pieces); 4 mg box (100-110 pieces)
3
Treatment of 8 weeks or less as efficacious as longer periods
4
A 10 mg cartridge delivers a 4 mg dose
5
Dose depends on nicotine dependence
2

Abbreviations: h-hour, NMT- no more than
Source: Fiore MC, Jaén CR, Baker TB et al. Treating tobacco use and dependence: 2008
update. Clinical Practice Guideline ed. Rockville, MD: Department of Health and Human
Services. Public Health Service; 2008.33
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Effectiveness of nicotine replacement therapies has been widely established, with
well over 3,000 studies published to date. In meta-analyses, NRT in all forms exhibited
similar efficacy, doubling cessation rates when compared to no therapy.43-45 Results of
meta-analyses of bupropion and varenicline confirm that these non-nicotine agents are
more effective than NRT in producing abstinence.46-49 When NRT products are used in
combination with other NRT agents or in combination with non-nicotine products, they
produce even higher rates of cessation than any pharmacotherapy alone. Combination
NRT and non-nicotine medication therapy is well tolerated. Pharmacotherapies for
smoking cessation are highly cost-effective; this is well established in the literature.
Incremental cost-effectiveness figures in smoking cessation typically fall well below
established thresholds of $20,000/life-year saved and $50,000/QALY.50
When treatments with first-line therapies fail, two second-line non-nicotine
agents, clonidine and nortriptyline, can be used to aid in smoking cessation.33 Clonidine
is a hypertensive agent available as a tablet or transdermal patch for smoking cessation
treatment. Dosing ranges from 0.10-0.75 mg/daily (oral) or 0.10-0.20 mg/daily
(transdermal) for up to 12 weeks. Though well-tolerated, clonidine use is associated with
dry mouth, drowsiness, dizziness, and sedation. Clonidine cannot be stopped abruptly; is
must be tapered to avoid sharp increases in blood pressure and catecholamine levels.
Nortriptyline is an older antidepressant that can be used second-line for smoking
cessation. Its mechanism of action (in tobacco dependence) is largely unknown. Dosing
begins at 25 mg daily, and typically increases to 75 mg or 100 mg for up to 12 weeks.
Common side effects include sedation, dry mouth, lightheadedness, and shaky hands.
Abrupt discontinuation of nortriptyline can cause withdrawal; patients must be carefully
monitored when using this agent for smoking cessation. Neither of these agents has been
FDA-approved for smoking cessation; however, adequate evidence of efficacy and safety
exists.
Behavioral Counseling
Behavioral counseling is a viable alternative or adjunct to pharmacotherapy for
smoking cessation. Counseling is usually individually tailored, ranges from brief advice
to intensive counseling, and is conducted through various media (i.e. in person, by
telephone, via internet or printed materials). Group counseling methods also exist, but
will not be discussed here. Counseling on smoking cessation is generally provided by
primary care clinicians, but can be delivered by other health professionals (i.e. nurses,
pharmacists, dentists, psychologists) across a variety of settings (i.e. hospitals, clinics,
quitlines). The physician/patient encounter is an optimal opportunity to provide practical
counseling (problem-solving). This type of behavioral counseling educates smokers on
recognizing situations that trigger smoking/relapse, developing coping skills, and
emphasizing the dangers of smoking and the benefits of quitting. Intra- and extratreatment social support counseling can also utilized. Here, practitioners provide
additional support, encouraging patients to express their concerns about quitting and
identifying external support systems to aid patients through the cessation process.
As an alternative to face-to-face counseling, telephone quitlines provide an
effective medium for targeting smokers to encourage cessation. Quitlines eliminate most
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barriers associated with face-to-face counseling, including transportation,
patient/provider availability, and cost.51 Consequently, quitlines can reach more smokers,
especially vulnerable groups for whom services are not offered. California initiated the
first publicly funded telephone quitline in 1992 as part of its state tobacco control
program.51,52 By 2004, 37 other states had established their own; all states now operate
quitlines. In the last decade, quitline use increased substantially enough to be analyzed
separately in the 2008 Guidelines.33
Like pharmacotherapy, behavioral counseling methods have proven effective
across a variety of settings and smoking populations. Behavioral counseling is widely
used for pregnant smokers, due to inadequate evidence to confirm the efficacy and safety
of pharmacotherapy use.53 Meta-analyses show that brief counsel by a health professional
provides some benefit, but increased intensity of counseling (increased number or length
of sessions) is associated with more than a two-fold increase in cessation rates.33 Due to
its established efficacy, the U.S. Public Health Service now recommends that health
professionals screen all patients for smoking status and advise smokers on strategies for
quitting. Counseling is appropriate for all smokers, though the strategy employed is
determined by the patient’s motivation to quit. At minimum, every smoker should be
counseled on the five “A”s, as detailed by the Guidelines:53
1.
2.
3.
4.
5.

Ask all patients whether they smoke and if they are interested in quitting.
Advise patients about the health risks associated with tobacco use and the
benefits of quitting.
Assess a patient’s readiness to quit. For example, is the patient ready to
quit in the 1-6 months?
Assist in the quit process by educating patients about strategies such as
adding pharmacotherapy and making behavioral changes, which will
improve their success.
Arrange for follow-up by phone or in person to improve the patient’s
likelihood for success.

For smokers motivated to quit, this initial session should yield a viable strategy for
cessation. If a smoker is not yet motivated, clinicians should probe for potential barriers
to cessation and continue emphasizing the 5 “A”s, risks associated with smoking, as well
as benefits of cessation during subsequent visits.
Despite its effectiveness, use of behavioral counseling is challenged by several
factors. Research indicates that disparities in the provision and utilization of counseling
persist. Cokkinides et al. demonstrated in analyses of 2000 and 2005 National Health
Interview Survey (NHIS) data that compared to whites, black and Hispanic smokers were
significantly less likely to be screened for tobacco use, receive advice to quit, or use
tobacco cessation treatment.54, 55 Across the two survey periods, receipt of advice to quit
among smokers surveyed increased only modestly (53% to 61%). Despite the increased
reach of quitlines, they too are underutilized. In a qualitative review of surgical patients
and providers, Warner et al. found that both groups had limited knowledge of quitlines.56
Providers indicated willingness to refer patients to quitlines, but reported time as a key
barrier to receiving training in smoking cessation interventions. A report of quitline
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operations for 2004 revealed that most quitlines offered proactive versus reactive
counseling (89.5% versus 62.2%), mainly through proactive referrals from physicians.51
While proactive telephone counseling is considered effective, little research has been
conducted to establish the efficacy of smoker-initiated telephone counsel relative to other
methods.57 In addition, Sood et al highlights that smokers may not be interested in
intensive counseling methods, which among highly dependent smokers may be necessary
for cessation.57
Future Efforts
Tobacco control efforts have contributed to the significant decline in smoking
prevalence, now reduced by nearly half. The decline in tobacco use has produced a
resultant decline in mortality, though life expectancy increases have yielded an increasing
proportion of deaths caused by the chronic diseases associated with smoking—primarily
cancer, cardiovascular disease, and emphysema.3 However, much work remains. Hughes
purports that smokers able to quit have already done so, leaving older recalcitrant
smokers likely exhibiting higher levels of nicotine dependence, depression, and comorbid
substance abuse.58 A review of cessation interventions among these smokers indicate a
lack of responsiveness to treatment.59 Newer cessation methods have been proposed to
address this more difficult-to-treat smoking population.
Stepped Care for Tobacco Cessation
Stepped care has surfaced as an intensive approach that could possibly improve
long-term cessation rates among smokers. Stepped care is defined as the practice of
initiating treatment with low-intensity intervention, exposing treatment failures to more
intense intervention at subsequent steps until the desired outcome is reached. Stepped
care is not an intervention in itself. Rather, it is a way to sequence interventions so that
the intensity, complexity, and costs of care are guided by each patient’s observed
outcome.60 Stepped care, as a treatment approach, has been employed extensively in the
management of hypertension. Current and previous reports of the Joint National
Committee on Prevention, Detection, Evaluation, and Treatment of Blood Pressure
present a hypertension stepped care algorithm combining empirically validated treatment
strategies in three areas: lifestyle modification, first-line pharmacologic agents, and
second-line combination regimens. Treatment recommendations vary depending on risk,
degree of blood pressure elevation, evidence of target organ damage, and presence of
cardiovascular disease, medication side effects, and other risk factors.61 Stepped care is
advocated in various guidelines for treatment of asthma,62 rheumatoid arthritis,63
diabetes,64 depression,65 and has been explored in treatment of various chronic disorders
including back pain,60 migraine,66 obesity,67 eating disorders,68 multiple sclerosis,69
alcohol dependence,70-72 and heroin dependence.73
Evidence of the efficacy of stepped care in treating nicotine dependence has not
been established; only a few published studies exist investigating this new approach.74, 75
Reid and colleagues examined the viability of stepped care among 254 smokers
hospitalized with coronary artery disease.74 Patients were randomized to receive either
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usual care, consisting of brief counsel, or intensive stepped care, which combined brief
counsel and pharmacotherapy. After three months, short-term cessation rates favored
stepped care, but this trend was not sustained at one year. The authors attributed the
results to timing and content of the stepped care intervention. Specifically, initial
treatment was limited by duration of inpatient stay, and patients were not followed up
until four weeks post-discharge. This delay in assessing quit status made it difficult to
prevent relapse in the interim. For relapsers, three counseling sessions and up to eight
weeks of nicotine replacement therapy were offered, which showed benefit only at three
months. Similarly, a study by Smith and colleagues failed to demonstrate that either of
two stepped care treatments improved long-term cessation above brief intervention.75
They too attributed poor results to a one week delay in offering step up therapy, a period
most critical to relapse. Thus, panel members contributing to the AHCPR guidelines have
not made a formal recommendation for stepped care approaches to smoking cessation.33
Purpose of Study
Stepped care provides a framework for achieving professional support for chronic
illness that is cost-effective and is based on patients' observed response to treatment.70 It
promotes efficient resource allocation, by exposing only treatment failures to more
intensive therapy.76 A current research study, CA106667: “Long-term Smoking Cessation
Using Prescription Step Care” (STEP), explores a novel, aggressive stepped care
approach to increasing tobacco cessation relative to a repeat therapy approach. However,
the stepped care approach in this study (relative to previous studies) more closely aligns
with methods in hypertensive care, in which therapy (pharmacologic and behavioral) is
intensified over a maximum of three steps to increase likelihood of cessation by study
end. Investigators expect the study to yield more favorable results than seen previously
because of its increased intensity and duration. Moreover, it is necessary to determine
cost-effectiveness of stepped care in smoking cessation, as only one study to date has
examined this.77 Thus, the purpose of this research is to use results from the
aforementioned STEP study to ascertain if stepped care relative to repeat care is a costeffective method for achieving tobacco cessation.
STEP is a multi-site study comprised of participants in Memphis, Tennessee and
Rochester, Minnesota. Participants are at least 18 years old and self-reported smokers of
at least 10 cigarettes per day, who have consented to participate in the research study.
This group serves as the cohort for the cost-effectiveness analysis. Though smokers
across both sites are typically one-pack-a-day smokers and have similar levels of nicotine
dependence, it is important to note the unique differences that exist among smokers
across study sites. Smokers in Memphis fit the typical demographic profile—they are
mainly low income and minority. The National Institutes of Health has deemed low
income and minority smokers as special populations which require greater study, as these
populations exhibit low rates of cessation, especially long-term. Minority race and low
socioeconomic status are factors which primarily drive disparities in tobacco cessation. In
addition, Memphis smokers in the sample have higher CES-D (Center for Epidemiologic
Studies Depression Scale) scores compared to Rochester smokers (9.84 vs. 7.59); CES-D
scores indicate severity of depressive symptoms. Smokers in Rochester, Minnesota are a
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strong contrast to those in Memphis; they are primarily Caucasian and have higher
income levels. In fact, minorities only comprise about 9% of the Rochester sample, as
compared to 50% in the Memphis sample. Recruitment through Mayo Clinic may
influence these differences as the recruited sample mirrors the Rochester, Minnesota
population. Baseline characteristics for the sample are detailed further in Chapter 3.
Specific Aims
Evaluate Cost-Effectiveness of the STEP Study
Data collected from the research study will be used to conduct a costeffectiveness analysis. The primary outcome of interest is incremental cost per quit for
stepped care versus repeat care. Although the research study defines three cessation
measures (point-prevalent, prolonged, and continuous) to be captured, point prevalent
and continuous abstinence are most commonly cited in previous studies and will be used
to calculate incremental cost per quit. Given the research setting, costs will reflect study
rates.
Use Study Outcomes to Simulate Future Health Consequences
Simulation models are widely used in healthcare interventions to simulate future
events. Results from the study can be used to predict changes in disease risk, incidence,
and mortality resulting from cessation. Use of simulation models (microsimulation,
discrete event simulation) in healthcare studies is gaining popularity. These methods
transcend the constraints of Markov modeling in their ability to better predict individuals’
movement through a disease or health process. Individual characteristics of study
participants are used as model inputs to simulate impacts of long-term cessation (i.e.
change in morbidity and mortality) in a diverse population and its resultant impact on
societal costs. Results of the simulation are presented as incremental cost per qualityadjusted life year (QALY). Because health-related quality of life measures are not
provided in the STEP study, synthetic estimates from the literature can be substituted.
Short-term and long-term STEP outcomes can then be analyzed against previous studies.
Compare Cost-Effectiveness Results to Previous Analyses
Results of the cost-effectiveness analyses for STEP will be compared to other
studies reviewed in the literature. By using multiple outcomes measures, study results can
be compared to a broad range of literature. Most cost-effectiveness analyses of smoking
cessation interventions use cost per quit as a primary measure. Cost per QALY is
generally the standard measure used in cost-effectiveness analyses of other major lifesaving health interventions; it allows for easier comparison and comprehension and
ultimately broadens the audience for whom cost-effectiveness research can benefit.
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Conceptual Framework of STEP Study
The conceptual framework which grounds the cost-effectiveness analysis is
derived from the framework of the original intervention, described in Figure 1-2. The
model is based on principles of social and operant learning and combines psychosocial,
neuropharmacologic, and environmental determinants of tobacco use at several levels.
At the top of the diagram, a variety of factors predispose individuals to smoking
including social (culture, socioeconomic status, media/family/peer influences),
psychological (comorbidity, personality, stress), and biological (genetics, nutrition)
factors. These and other factors, such as nicotine dependence or past attempts to quit, will
influence a smoker’s motivation to make one or more attempts to quit. Cessation
represents an opportunity for new learning (which opposes the previous learned behavior
of smoking); this will no doubt effect both one’s motivation to make a quit attempt and
his/her self-efficacy (belief about the ability to quit) (box 3). A novel approach (box 2) to
cessation can positively influence motivation to quit, outcomes expectancies, and
smokers’ belief in their ability to quit. It is expected that a novel approach will increase
readiness to quit (box 4) and lead to a quit attempt (box 5).
After a quit, risk of relapse exists, especially as nicotine withdrawal symptoms
surface. As seen in the diagram, predisposing factors (i.e. nicotine dependence) again will
influence risk factors which often lead to relapse. Negative affect or weight gain may
prompt smokers to resort to older learning, thus retuning to smoking. Therefore,
reinforcement is provided (i.e. phone calls, mailings) to discourage relapse and encourage
Predisposing Factors (1)
Dependence
Smoking history
Prior quit attempts
Demographics
Environmental factors

Dose

Pharmacologic

Novelty (2)

Behavioral

Risk and Protective
Factors for Relapse (6)

Cognitive Factors
(3)
Motivation
Outcome
expectancies
Self-efficacy

Maintenance
(7)

Readiness
(4)

Quit
Attempt
(5)

Recycle
(9)

Withdrawal
Negative affect
Weight change
Social support
Exposure to smokers
Situational crises
Relapse (8)

Figure 1-2. Conceptual Framework of STEP Study
Source: Klesges, RC. Step Care Manual of Procedures. 2006: p.11 (unpublished).78
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maintenance of cessation (box 7). Smoking status is determined several weeks following
treatment; in case an individual returns to smoking (box 8), a smoker is recycled quickly
(box 9) into a renewed quit attempt. For stepped care patients who relapse, the dose of
pharmacological and behavioral therapy is “stepped up”; this intensified intervention is
presented as new novel approach to make another quit attempt. Stepped care offers a new
opportunity for learning at each quit attempt; by presenting an alternative novel therapy,
motivation, outcome expectancies, and self-efficacy remain positive instead of becoming
negative. Smokers offered stepped care will be more likely to make additional quit
attempts. Each new attempt increases one’s likelihood of cessation through an increased
number of trials. Over time, the probability of quitting is expected to increase with the
number of quit attempts in a negatively accelerated pattern.
Significance
Several factors justify significance of this research. First, the underlying
intervention evaluates a new method for smoking cessation. Given the current difficulties
of achieving both short- and long-term cessation among smokers ready to quit, providing
a new approach can boost cessation efforts across the United States and abroad.
Moreover, this intervention features a significant portion of minority and low-income
smokers; cessation has proven far more difficult to achieve in this population. These
results will inform current research on establishing effective interventions to achieve
cessation in key populations. In the most recent AHCPR guidelines, Fiore and colleagues
highlight low-income individuals and racial/ethnic minorities as special populations for
which more effective intervention is needed.33 In addition, they stated that stepped-care
interventions in smoking cessation warranted further research, due to its paucity in
current practice.
The economic evaluation connected to the intervention will contribute positively
to a growing body of literature assessing cost-effectiveness of smoking cessation studies
and programs. O’Sullivan, Gold, and others contend that conducting economic evaluation
alongside studies is feasible and convenient.79, 80 Growth in this area of the literature is
critically necessary to inform policymakers of the value of smoking cessation to society.
Currently, the lack of standards in the use of cost-effectiveness for funding smoking
cessation has resulted in sub-optimal uptake in the coverage of such programs across
health plans. Several studies have demonstrated both increased participation and
improved outcomes in cessation health plan-sponsored programs that cover all or part of
costs. These benefits are enhanced with coverage of related pharmacologic therapies to
help more smokers kick their habits.
Additionally, the growing burden of U.S. healthcare costs on taxpayers,
businesses, and government will build evidence to encourage the government to establish
national standards for economic evaluation of new drug therapies and disease
management programs, and set thresholds for justification of coverage. Many countries
already mandate cost-effectiveness analysis as a requirement for approval and coverage
of new drug therapies, and have realized significant cost savings.
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Definition of Terms
•

Biochemical verification. The use of biological samples (expired air, blood,
saliva, or urine) to measure tobacco-related compounds such as thiocyanate,
cotinine, nicotine, and carboxyhemoglobin to verify users’ reports of abstinence.

•

Bupropion (bupropion). A non-nicotine aid for smoking cessation, originally
developed and marketed as an antidepressant. It is chemically unrelated to
tricyclics, tetracyclics, selective serotonin re-uptake inhibitors, or other known
antidepressant medications. Its mechanism of action is presumed to be mediated
through its capacity to block the reuptake of dopamine and norepinephrine
centrally. Marketed as Zyban for smoking cessation.

•

Cost-effectiveness. A ratio of costs incurred and averted by a particular treatment
or service and the benefits achieved by treatment/service.

•

Efficacy. The outcome achieved from a treatment provided under near-ideal
circumstances of control (typically, in a research study). Efficacy studies involve
recruitment of motivated participants, random assignment, intensive assessment,
and methods designed to keep participants in treatment.

•

Environmental tobacco smoke (ETS). Also known as “secondhand smoke”
(SHS) or passive smoke. The smoke inhaled by an individual not actively
engaged in smoking, but who is exposed to smoke from the lit end of a cigarette
and the smoke exhaled by the smoker.

•

Failure (treatment). Defined by self-reported relapse or abnormal biochemical
measure (expired carbon monoxide or cotinine measure)

•

Intensive interventions. Comprehensive treatments that may occur over multiple
visits for long periods of time and may be provided by more than one clinician.

•

Intervention. An action or program that aims to bring about identifiable
outcomes. In tobacco dependence treatment, the intervention generally is clinical
in nature and may consist of counseling and the use of medications. Also referred
to as “treatment.”

•

Nicotine gum. Nicotine-containing gum, a smoking cessation aid, that delivers
nicotine through the oral mucosa. It is available without a prescription.

•

Nicotine patch. A nicotine-containing patch, a smoking cessation aid, that
delivers nicotine through the skin; available with or without a prescription.

•

Nicotine replacement therapy (NRT). Refers to medications containing nicotine
that are intended to promote smoking cessation. There are five NRT delivery
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systems currently approved for use in the United States. These include nicotine
gum, nicotine inhaler, nicotine lozenge, nicotine nasal spray, and nicotine patch.
•

Point prevalence abstinence. A measure of tobacco abstinence based on
smoking/tobacco use occurrence within a set period (usually 7 days), prior to a
follow-up assessment.

•

Prolonged abstinence. A measure of tobacco abstinence based on whether
subjects are continuously abstinent from smoking/tobacco use from their quit day
to a designated outcome point (e.g., end of treatment, 6 months after the quit day).

•

Quality-adjusted life years (QALY). Measure of both the quality and the
quantity of life lived. Used as a means of quantifying the benefits of a medical
intervention.

•

Quit. Successful cessation attempt, reported by self-reported or biochemically
verified abstinence (where appropriate).

•

Randomized controlled trial. A study in which subjects are assigned to
conditions on the basis of chance, and where at least one of the conditions is a
control or comparison condition.

•

Relapse. Return to regular smoking by someone who has quit. A distinction is
sometimes made between “relapse” and a “lapse” (or a “slip”), which is a return
to reduced smoking or brief smoking after quitting that falls short of a return to
regular smoking.

•

Self-reported abstinence. Abstinence based on the patient’s claim, which may or
may not be verified clinically by biochemical confirmation.

•

Serum nicotine. Level of nicotine in the blood. This often is used to assess a
patient’s tobacco/nicotine self-administration prior to quitting, and to confirm
abstinence self-reports during follow-up. Nicotine commonly is measured in urine
and saliva.

•

Serum nicotine/cotinine levels. Level of nicotine/cotinine in the blood. Cotinine
is nicotine’s major metabolite, which has a significantly longer half-life than
nicotine. This often is used to estimate a patient’s tobacco/nicotine selfadministration prior to quitting, and to confirm abstinence self-reports during
follow-up. Cotinine commonly is measured in urine and saliva.

•

Smoker. A person that uses tobacco products in any form.

•

Smokeless tobacco. Any form of unburned tobacco, including chewing tobacco,
snus, and snuff. Smokeless tobacco can cause cancer of the gum, cheek, lip,
mouth, tongue, throat, and pancreas.
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•

Stepped care. The practice of initiating treatment with a low-intensity
intervention and then exposing treatment failures to successively more intense
interventions.

•

Tobacco dependence. Dependence on any form of tobacco, including, but not
exclusive to, cigarettes, pipes, cigars, and chewing tobacco.

•

Varenicline. A non-nicotine aid for smoking cessation, and the first partial
agonist of the α4β2 neuronal nicotinic acetylcholine receptor to be developed. It is
presumed to work by preventing nicotine binding to α4β2 receptors. Varenicline
is marketed in the United States as Chantix.

•

Withdrawal symptoms. A variety of unpleasant symptoms (e.g., difficulty
concentrating, irritability, anxiety, anger, depressed mood, sleep disturbance, and
craving) that occur after use of an addictive drug is reduced or stopped.
Withdrawal symptoms are thought to increase the risk for relapse.
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CHAPTER 2: LITERATURE REVIEW
Introduction
In WHO’s 2008 report, six major policies are introduced that, when enacted
together, will help prevent young people from initiating smoking, help current smokers
quit, and protect nonsmokers from unnecessary secondhand exposure.2 Offering to help
smokers quit is a key policy that encourages use of low-cost, effective interventions to
increase cessation. Currently, such programs exist in nine countries, representing 5% of
the world’s smoking population. Thus, information on cost-effectiveness of smoking
cessation interventions is critical to justify funding of future studies and coverage of
smoking cessation programs for smokers.
To this end, a review of literature of cost-effectiveness analyses in smoking
cessation was conducted. The PubMed database was queried to identify full-text articles
(including literature reviews and meta-analyses) that met these criteria: a) smoking
cessation clinical trials/studies analyzing (or simulating) either a stepped care
intervention or a moderate/intensive pharmacotherapy and counseling intervention, b) a
cost-effectiveness component, c) face-to-face contact for interventions (versus telephone
or mail contact only), and d) end-of-study follow-up of at least 12 months post initiation.
These specific criteria were necessary for relevant comparison to the Step Care study.
Articles had to clearly state a perspective (i.e. societal, third-party payer), cessation and
outcomes measures, patient population, and duration of follow-up to be considered for
review. Articles using return on investment or cost-benefit techniques or those analyzing
cost-effectiveness of anti-smoking policies or taxes (instead of treatments or programs)
were excluded. Analyses conducted in other countries were included as long as articles
were printed in English and met all other criteria. Medical Subject Heading (MeSH)
terms (costs and cost analysis, tobacco use cessation/economics) produced close to 100
full-text results; only nine met inclusion criteria. Following a brief overview, studies were
analyzed in two areas: comparisons of cost-effectiveness and adherence to widely
accepted recommendations for conduct of economic evaluations.
Overview of Smoking Cessation Studies
Nine studies utilizing intervention designs most comparable to the underlying
study are reviewed to estimate an expected range of cost-effectiveness for the Step Care
Study. Considering that these studies use shorter treatment periods, it is expected that
they will provide a lower bound for expected cost-effectiveness of Step Care. The studies
reviewed assess the impact of smoking cessation interventions across varied time
horizons (18 months to lifetime); Table 2-1 outlines study characteristics. Only one study
(Barnett)77 among those reviewed analyzed cost-effectiveness of a stepped care
intervention (relative to brief intervention); all others compared brief interventions to
other moderate or intensive interventions. Short-term studies analyzing intermediate
outcomes (i.e. cost per quit) are reviewed separately from those analyzing long-term
outcomes (i.e. cost per life-year saved, cost per QALY).
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Table 2-1. Study Characteristics: Cost-Effectiveness Analyses of Smoking Cessation
Interventions

Characteristics
Methods
Analysis type
Model type
Framing
Country
Setting

Intervention

Study, Year
Bolin et al. (2006)

Barnett et al. (2008)
Prospective CEA
decision tree

Prospective CEA
simulation model

Prospective CEA
Markov model

United States
322 smokers in a
mental health
outpatient setting

Sweden
Model cohort of
male & female
smokers,
proportionate to
Swedish population
1. Bupropion

Switzerland
simulated twin
cohorts of one PAD
smokers

1. Brief counsel and
list of SC programs
(reference)
2. Stepped care*

2. Nicotine gum
3. Nicotine patch

Perspective
Time horizon

Cornuz et al. (2003)

1. Counseling only
from GP (reference)
2. Counseling plus
gum
3. Counseling plus
patch
4. Counseling plus
spray
5. Counseling plus
inhaler
6. Counseling plus
bupropion

Research
18 month follow-up
following treatment

Societal
20-year follow-up

Third-party payer
12 month follow-up
following treatment

Effects
Cessation
Main effects

Point-prevalence
1. C/Q

Continuous
1. C/QALY

Point-prevalence
1. C/LYS

Discount rate

N/A

3%

3%

Base year (costs)

2003

2001

2001
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Table 2-1. (continued)

Characteristics
Methods
Analysis type
Model type
Framing
Country
Setting

Intervention

Cornuz et al. (2006)
Prospective CEA

Gilbert et al. (2004)
Prospective CEA

Markov model

CEA of cessation
programs
simulation model

Multiple countries
simulated twin
cohorts of one PAD
smokers

The Netherlands
simulated cohort of
Netherlands
population

Seychelles
simulated twin
cohorts of one PAD
smokers

1. Counseling only
from GP (reference)
2. Counseling plus
gum
3. Counseling plus
patch

1. Minimal
counseling (MC)
2. MC + NRT

1. Counseling only
from GP (reference)
2. Counseling plus
gum
3. Counseling plus
patch

4. Counseling plus
spray
5. Counseling plus
inhaler
6. Counseling plus
bupropion
Perspective
Time horizon

Study, Year
Feenstra et al.
(2005)

3. Intensive
counseling (IC) +
NRT
4. IC + Bupropion
5. Telephone
counseling (TC)
6. Current practice
(reference)

Markov model

4. Counseling plus
spray
5. Counseling plus
inhaler
6. Counseling plus
bupropion

Third-party payer
12 month follow-up
following treatment

Societal
75 years

Third-party payer
12 month follow-up
post treatment

Point-prevalence

Point-prevalence

1. C/LYS

Prolonged
abstinence
1. C/Q
2. C/LYS
3. C/QALY

Discount rate

3%

4%

3%

Base year (costs)

2001

2000 (euros)

2003

Effects
Cessation
Main effects

20

1. C/LYS

Table 2-1. (continued)

Characteristics
Methods
Analysis type
Model type
Framing
Country
Setting

Intervention

Study, Year
Wasley et al. (1997)

Hall et al. (2005)

Woolacott (2002)

Retrospective CEA
decision tree

Prospective CEA
decision model

Prospective CEA
decision model

United States
220 cigarette
smokers

United States
Hypothesized
sample of
established PAD
smokers
1. Counsel
(reference)

United Kingdom
Hypothesized
sample of
established United
Kingdom smokers
1. Counsel only
(reference)

2. Counsel + patch

2. NRT + counsel
3. Bupr + counsel
4. NRT + Bupr +
counsel

1. Medical
management (MM)
(reference)
2. MM + PI
3. MM + Nortrip
4. MM + Bupr

Perspective

Third-party payer

Time horizon

52 weeks following
initiation

Patient

Third-party payer
(NHS)
12 months following Lifetime
treatment

Effects
Cessation
Main effects

Point-prevalence
1. C/Q

Point-prevalence
1. C/Q
2. C/LYS

Point-prevalence
1. C/Q
2. C/LYS
3. C/QALY

Discount rate

N/A

5%

1.5% (effects only)

Base year (costs)

2000

1995

1998

Note: *Stepped care involves: 1) up to 3 assessments of Readiness to Quit, 2) NRT and 6
counsel sessions, and 3) Bupropion and 2 additional counsel sessions.
Abbreviations: CEA: cost-effectiveness analysis; C/LYS: cost per life-year saved; C/Q:
cost per quit; C/QALY: cost per quality adjusted life-year; G: gum; GP: general
practitioner; I: inhaler; IC: intensive counseling; MC: minimal counseling; MI:
motivational interviewing; MM: medical management; N/A: not applicable; NHS:
National Health Service (United Kingdom); NRT: nicotine replacement therapy; P: patch;
PAD: pack-a-day (20+ cigarettes); PI: psychological intervention; RCT: randomized
controlled trial; SC: smoking cessation; TC: telephone counseling.
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Short-Term Studies
Barnett et al. randomized 322 smokers in a mental health outpatient setting to a
brief contact intervention (comprising one counseling session and a list of available
smoking cessation programs) or a stepped care intervention.77 Stepped care participants
were offered up to three assessments of readiness to quit; contemplators or requestors of
therapy were then offered six counseling sessions and 10 weeks of nicotine replacement
therapy. Two additional counseling sessions and bupropion pharmacotherapy were
offered as a third step, upon relapse. Point-prevalence abstinence (7-day) was verified at
3,6,12, and 18 months. At study end, 24.6% of stepped care participants versus 19.1% of
brief contact were abstinent, at an incremental cost of $6,204 per additional quit.
Hall et al. examined incremental cost-effectiveness of bupropion, nortriptyline,
and psychological intervention when added to medical management among San
Francisco area volunteers participating in a clinical trial.81 Here, medical management
comprised four brief counseling sessions in which physicians gave advice to quit,
medication education and monitoring, and other materials, while psychological
intervention involved five group sessions, providing more in-depth counsel and support.
Nortriptyline and bupropion were pharmacotherapy options; all interventions were
conducted over 12 weeks. Seven-day point prevalence abstinence was verified at end of
treatments and at weeks 24, 36, and 52. Incremental cost-effectiveness estimates for
psychological intervention, nortriptyline, and bupropion were $440, $741, and $1,509 per
quit, respectively. Hypothesis testing revealed that differences in cost-effectiveness of
therapies were not significant.
Long-Term Studies
Bolin et al. evaluated the cost-effectiveness of bupropion and motivational
support relative to NRT (patch and gum) and motivational support for a cohort of
smokers simulating the Swedish population.82 A model was constructed to analyze
treatment costs incurred, healthcare costs averted (due to decreased risk of disease), and
productivity gains realized due to smoking cessation over a 20-year horizon. A variety of
external data sources were used for estimating quit, relapse, disease incidence, and
mortality rates and treatment costs that were entered into the model. Bupropion was
dominant to both nicotine gum and nicotine patch therapies for men and women in the
simulation when direct and indirect costs of smoking cessation were considered;
bupropion was less costly and more effective, producing net cost savings. However,
when only direct costs were considered, bupropion remained dominant only when
compared to nicotine gum therapy. Bupropion was cost-effective (more costly but more
effective) relative to nicotine patch therapy, with incremental cost-effectiveness
expressed in Swedish currency (6,600 SEK/QALY [men], 4,900 SEK/QALY [women]).
Cornuz et al. used Markov modeling to simulate twin cohorts of one pack-a-day
smokers in Switzerland to analyze cost-effectiveness of adding first-line smoking
cessation therapies to counseling alone.83 The reference cohort was offered routine
counseling at office visits; the other cohort received, in addition to initial counseling, an
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offer for pharmacotherapy (gum, patch, spray, inhaler, bupropion). Smokers accepting
pharmacotherapy received 5 additional follow-up consultations throughout treatment.
The models used reference studies reporting point-prevalence abstinence at 12 months. A
model was run for each of the five pharmacotherapies. Adding bupropion to counseling
was most cost-effective, ranging from €1,768 to €3,646 (currency in euros), followed by
the patch (€3,113 to €6,423), spray (€3,669 to €7,570), inhaler (€3,700 to €7,634), and
then gum (€4,266 to €8,799).
Cornuz published a follow-up study in 2006, updating estimates from Switzerland
and adding data from Canada, France, Spain, United States, and United Kingdom.84 Twin
cohorts were simulated for each country to assess the adjunct of first-line
pharmacotherapies to counseling alone. Again, adding bupropion was most cost-effective
for men and women, followed by patch, spray, gum, and inhaler. Incremental costs per
life-year saved for men ranged from $792 in Canada to $1,934 in the U.S., $1,758 in
Spain to $3,396 in United Kingdom, $1,935 in Spain to $5,275 in the U.S., $2,230 in
Spain to $5,509 in the U.S., and $3,480 in Switzerland to $5,759 in France for bupropion,
patch, spray, gum, and inhaler therapies, respectively. Incremental costs per life-year
saved for women ranged from $1,196 in Canada to $2,922 in the U.S., $2,657 in Spain to
$5,131 in United Kingdom, $2,923 in Spain to $7,969 in the U.S., $3,370 in Spain to
$7,643 in the U.S., and $5,257 in Switzerland to $8,700 in France for bupropion, patch,
spray, gum, and inhaler therapies, respectively.
Feenstra et al. analyzed cost-effectiveness of increased implementation of five
face-to-face interventions (minimal counseling with and without NRT, intensive
counseling with NRT or with bupropion, and telephone counseling) over current practice
in the Netherlands.85 Using modeling techniques, the number of additional quitters and
subsequent life-years and quality-adjusted life-years gained were estimated assuming
increased implementation of interventions over 1, 10, and 75 years for each intervention.
Researchers used available country data to estimate cessation, natural quit, and relapse
rates as well as intervention costs. Minimal counseling as a strategy dominated current
practice, as it was less costly and more effective (yielding 45 additional quits for $680
less per 1000 smokers). Permanent increased implementation (75 years) yielded the most
favorable results, with incremental costs of €1,400, €1,800, €4,300, and €6,200 per lifeyear gained for telephone counseling, minimal counseling and NRT, intensive counseling
and bupropion, and intensive counseling with NRT, respectively. Incremental costs per
QALY were more attractive at €1,100, €1,400, €3,400, and €4,900 for the
aforementioned therapies.
Gilbert et al. estimated incremental cost-effectiveness of first-line
pharmacotherapies over physician counseling alone in Seychelles to justify the provision
of pharmacotherapies in developing countries.86 The authors used a model validated by
Cornuz, simulating identical smoker cohorts that receive either physician counseling or a
combination of counseling and pharmacotherapy. The model was run for each of five
first-line pharmacotherapies. Adding bupropion was most cost-effective, followed by
patch, gum, inhaler, and spray. This order differed from Cornuz’s findings mainly
because of variations in drug prices across countries.
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Wasley et al. explored cost-effectiveness of providing nicotine patch therapy as an
adjunct to brief counseling.87 Using data from meta-analysis and other literature,
incremental cost per life-year saved was calculated for identical cohorts of 400 U.S.
pack-a-day smokers. Nicotine patch therapy was relatively cost-effective, ranging from
$1,796 to $4,391 per life-year saved depending upon gender and age.
Woolacott et al. used data from previous meta-analyses and cost-effectiveness
analyses to assess incremental cost-effectiveness of adjunct smoking cessation strategies
(nicotine replacement therapy, bupropion, and combination therapy) versus counseling
only for the United Kingdom population.88 A decision model was developed to estimate
costs and effects of the various strategies by cost per quit, cost per life-year saved, and
cost per QALY. As seen with other studies, bupropion and counseling was the most costeffectiveness strategy, with ICERs of £1,278 per quit, £639 per life-year saved, and £473
per QALY (currency in pounds). Nicotine replacement therapy and bupropion and
counseling produced ICERs of £1,781 per quit, £890 per life-year saved, and £660 per
QALY. Nicotine replacement therapy and counseling produced ICERs of £2,001 per quit,
£1,000 per life-year saved, and £741 per QALY.
Comparisons of Cost-Effectiveness
Cost-effectiveness analyses of life-saving interventions are often displayed in
league tables, which allow study results to be compared. Due to differences in
perspective, setting (country), and cost-effectiveness outcomes, results of studies must
first be equalized to allow for comparison. In order to achieve equivalence across studies,
incremental cost-effectiveness estimates required conversion to current year dollars,
using a historical exchange rate database for exchanging foreign currencies to the U.S.
dollar and the consumer price index (CPI) to update estimates to the year 2009. The
studies were separated by geography (U.S. versus international) and effect (cost per quit,
life-year saved, QALY) to evaluate the ranges of incremental cost-effectiveness across
studies. Tables 2-2 and 2-3 summarize cost-effectiveness of international and U.S.
studies, respectively.
Among international studies, smoking cessation interventions were extremely
cost-effective, ranging from $768-$5,067/quit, $954-$11,601/LYS, and $1,008$8,872/QALY. U.S.-based interventions were equally cost-effective, ranging from $545$7,189/quit and $2,513-$6,019/LYS. These figures are small in comparison to the costs
of other healthcare interventions; mammography screening or treatment for high
cholesterol are $50,000 and $100,000/LYS, respectively.33 In 1995, Tengs and colleagues
reviewed 500 life-saving interventions; overall, the median medical intervention cost
$19,000 per life-year saved (or $27,228 in 2009 dollars).50 The cost-effectiveness of
smoking cessation treatments is more evident when comparing incremental cost/QALY.
Incremental costs for smoking cessation interventions are at most a tenth of the accepted
threshold of $50,000/QALY.
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Table 2-2. League Table of International Cost-Effectiveness Analyses of Smoking
Cessation Interventions
Author
Feenstra et al.
Woolacott et al.
Feenstra et al.
Feenstra et al.
Woolacott et al.
Feenstra et al.
Woolacott et al.
Feenstra et al.

Intervention
Cost ($, 2009)
Cost/Quit
MC vs. Current Practice
$768
Counsel + Bupr vs. Counsel
$2,723
TC vs. Current Practice
$2,798
MC + NRT vs. Current Practice
$2,986
Counsel + NRT + Bupr vs. Counsel
$3,795
IC + Bupr vs. Current Practice
$4,112
Counsel + NRT vs. Counsel
$4,264
IC + NRT vs. Current Practice
$5,067

Feenstra et al.
Cornuz et al. (2006)
Woolacott et al.
Cornuz et al. (2006)
Gilbert et al.
Woolacott et al.
Cornuz et al. (2006)
Woolacott et al.
Gilbert et al.
Cornuz et al. (2006)
Gilbert et al.
Feenstra et al.
Cornuz et al. (2006)
Cornuz et al. (2003)
Feenstra et al.
Cornuz et al. (2006)
Cornuz et al. (2006)
Gilbert et al.
Cornuz et al. (2003)
Cornuz et al. (2006)
Cornuz et al. (2006)
Gilbert et al.
Gilbert et al.
Cornuz et al. (2003)
Gilbert et al.
Cornuz et al. (2003)

Cost/Life-Year Saved
MC vs. Current Practice
Counsel + Bupr vs. CO (Males)
Counsel + Bupr vs. Counsel
Counsel + Bupr vs. CO (Females)
Counsel + Bupr vs. CO (Males)
Counsel + NRT + Bupr vs. Counsel
Counsel + Patch vs. CO (Males)
Counsel + NRT vs. Counsel
Counsel + Patch vs. CO (Males)
Counsel + Spray vs. CO (Males)
Counsel + Bupr vs. CO (Females)
TC vs. Current Practice
Counsel + Gum vs. CO (Males)
Counsel + Bupr vs. CO (Males)
MC + NRT vs. Current Practice
Counsel + Patch vs. CO (Females)
Counsel + Spray vs. CO (Females)
Counsel + Patch vs. CO (Females)
Counsel + Bupr vs. CO (Females)
Counsel + Gum vs. CO (Females)
Counsel + Inhaler vs. CO (Males)
Counsel + Gum vs. CO (Males)
Counsel + Inhaler vs. CO (Males)
Counsel + Patch vs. CO (Males)
Counsel + Spray vs. CO (Males)
Counsel + Spray vs. CO (Males)
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cost-saving
$954-$2,330
$1,362
$1,441-$3,520
$1,519-$2,014
$1,896
$2,118-$4,091
$2,131
$2,273-$3,013
$2,331-$6,354
$2,378-$3,264
$2,389-$2,316
$2,686-$6,094
$2,935-$4,732
$3,071-$2,664
$3,200-$6,180
$3,521-$9,559
$3,558-$4,883
$3,562-$6,052
$4,059-$9,206
$4,192-$6,937
$4,258-$5,643
$4,922-$6,523
$5,167-$8,334
$5,273-$6,989
$6,090-$9,823

Table 2-2. (continued)
Author
Cornuz et al. (2003)
Cornuz et al. (2003)
Cornuz et al. (2006)
Gilbert et al.
Cornuz et al. (2003)
Feenstra et al.
Cornuz et al. (2003)
Cornuz et al. (2003)
Gilbert et al.
Gilbert et al.
Cornuz et al. (2003)
Feenstra et al.

Bolin et al.
Bolin et al.
Feenstra et al.
Woolacott et al.
Woolacott et al.
Woolacott et al.
Feenstra et al.
Feenstra et al.
Bolin et al.
Bolin et al.
Feenstra et al.
Feenstra et al.

Intervention
Cost ($, 2009)
Cost/Life-Year Saved
Counsel + Inhaler vs. CO (Males)
$6,141-$9,906
Counsel + Patch vs. CO (Females)
$6,272-$10,661
Counsel + Inhaler vs. CO (Females) $6,332-$10,479
Counsel + Gum vs. CO (Females)
$6,666-$9,147
Counsel + Gum vs. CO (Males)
$7,081-$11,418
IC + Bupr vs. Current Practice
$7,336-$8,019
Counsel + Spray vs. CO (Females)
$7,393-$12,565
Counsel + Inhaler vs. CO (Females) $7,456-$12,671
Counsel + Inhaler vs. CO (Females) $7,705-$10,573
Counsel + Spray vs. CO (Females)
$8,255-$11,329
Counsel + Gum vs. CO (Females)
$8,595-$14,605
IC + NRT vs. Current Practice
$10,578-$11,601
Cost/Quality-Adjusted Life-Year
Bupr vs. Patch (Males)
Bupr vs. Gum (Males)
MC vs. Current Practice
Counsel + Bupr vs. Counsel
Counsel + NRT + Bupr vs. Counsel
Counsel + NRT vs. Counsel
TC vs. Current Practice
MC + NRT vs. Current Practice
Bupr vs. Patch (Females)
Bupr vs. Gum (Females)
IC + Bupr vs. Current Practice
IC + NRT vs. Current Practice

cost-saving
cost-saving
cost-saving
$1,008
$1,406
$1,579
$1,877-$2,559
$2,389-$2,900
$2,539
$4,054
$5,801-$6,142
$8,360-$8,872

Abbreviations: Bupr: bupropion; CO: counsel only; IC: intensive counseling; MC:
minimal counseling; NRT: nicotine replacement therapy; PI: psychological intervention;
TC: telephone counseling.
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Table 2-3. League Table of U.S. Cost-Effectiveness Analyses of Smoking Cessation
Interventions
Author

Intervention
Cost/Quit
Hall et al.
MM + PI vs. MM
Hall et al.
MM + Nortrip vs. MM
Hall et al.
MM + Bupr vs. MM
Barnett et al. Stepped Care vs. Brief Intervention

Cost ($, 2009)
$545
$917
$1,868
$7,189

Cost/Life Year Saved
Wasley et al. Counsel + Patch vs. Counsel (Males)
$2,513-$4,126
Wasley et al. Counsel + Patch vs. Counsel (Females) $4,253-$6,143
Barnett et al. Stepped Care vs. Brief Intervention
$6,019
Abbreviations: Bupr: bupropion; IC: intensive counseling; MM: medical management;
Nortrip: nortriptyline; NRT: nicotine replacement therapy; PI: psychological intervention
Recommendations for Conduct of Economic Evaluation
While comparison of cost-effectiveness of smoking cessation programs,
treatments, and services is highlighted in this review, the underlying methodology is of
greater importance. Appropriate conduct of cost-effectiveness analysis in smoking
cessation is necessary for achieving greater comparability across studies and is critical to
designing the current analysis. Despite the existence of various guidelines addressing the
design of economic evaluations, the recommendations from the U.S. Panel on CostEffectiveness in Health and Medicine (The Panel) are widely cited and accepted as a
specific rubric for designing and conducting cost-effectiveness analyses.80 The Panel
outlines key elements for the appropriate conduct of economic evaluation.
Perspective
Perspective considers the point of view from which the study is designed. To
frame the research question(s) from a particular perspective will determine which costs
and consequences should be included. Costs and consequences will differ among
patients, third-party payers, employers, or society, thus yielding varied estimates of costeffectiveness. The Panel recommends framing cost-effectiveness analyses from a societal
perspective, to account for all costs and effects attributable to treatment, regardless of
who experiences them. Among reviewed studies, those which utilized a third-party payer
or governmental perspective represented health plans or countries with single-payer
healthcare systems. A broader search of the literature produced only four studies
published after the release of Panel guidelines framed from the societal perspective. A
few articles provide cost-effectiveness results from multiple perspectives—this is a
common and widely accepted approach, as it enhances homogeneity across studies.
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Measures of Cessation
Point prevalence abstinence was used as the measure of cessation in all studies
reviewed. This reflects its wide acceptance as a cessation measure. Many articles
specified 7-day point prevalence as the measure; in several studies, abstinence was
verified biochemically. Biochemical verification is commonly conducted at follow-up to
encourage valid self-report of abstinence, as various methods can detect nicotine
exposure up to three days prior to follow-up. Velicer and colleagues contend that
verification, though encouraged, is not necessary due to the rare nature of report
falsification.89 Though the specifics of cessation measures fall outside of Panel
recommendations, they are used to validate a quit, which is a common outcome measure
used in cost-effectiveness studies of smoking cessation.
Outcome Measures
Outcome measures provide the basis for calculating cost-effectiveness ratios.
These ratios are used to explain a program’s cost relative to achieving an effect. Outcome
measures can be disease-specific or generic. In the smoking cessation literature, number
of quits and life-years saved are more commonly used effects. These measures are
preferred because they are easy to comprehend among healthcare decision makers.
Among studies employing a societal perspective, cost per QALY is a standard, although
cost per quit and cost per life-year saved are often reported as well. Panel
recommendations encourage the use of a cost per QALY ratio, because it reflects the
value to achieve both longer and more productive life. In addition, cost-effectiveness
results should be reported as an incremental cost-effectiveness ratio, or the difference in
costs for an intervention versus its comparator divided by the difference in their effects.
None of the U.S. studies considered cost per QALY; only Barnett and Wasley’s studies
extended their analyses to consider cost per life-year saved.77, 87
Discounting
The Panel, in their recommendations, strongly supports the use of discounting. It
is necessary because costs and benefits in a study are not typically incurred within the
same year. In many cases, both costs and benefits can occur over two different time
horizons, thus necessitating discounting of costs and benefits. In a few cases, costs are
incurred in one year, while only benefits occur across several years; here, only benefits
should be discounted. A 3% discount rate should be applied to costs and effects as
appropriate, as well as an alternative 5% rate. The suggested rate reflects current
estimates of real economic growth, while the alternative rate accommodates comparison
across older studies, which often used 5% as a discounting standard. Justifications for
discounting were found in many studies; one such discussion is highlighted in the study
by Feenstra and colleagues.85 In their simulation, discounting accounts for delayed
accrual of health effects relative to the immediate accrual of intervention costs. Most
studies cited a discount rate of 3%;82-84, 86 another used 5%.87 Abroad, countries have
adopted alternate standards; the Dutch standard of 4% was noted in Feenstra’s study.85 In
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the United Kingdom, a rate 3.5% is recommended,90 although Woolacott’s study used
health effects discounted by 1.5%.88
Use of Modeling
Several studies utilize Markov modeling techniques to estimate, prospectively,
cost-effectiveness of proposed programs.82-86 Prospective cost-effectiveness analysis with
models can assist healthcare financing bodies in deciding whether it is beneficial or not to
offer and even to cover certain smoking cessation products, services, or programs. Data
extracted from clinical trials or other sources are used to estimate treatment course and
duration, probabilities of success, and resulting risks and costs of adverse events
(associated with treatment). Other literature sources are used to estimate physician time
and costs for intervention, administrative costs of intervention, patient’s costs for
transportation and lost work-time, and other appropriate costs (depending on the
perspective used). Examples of costing techniques are detailed in Cornuz’s and Gilbert’s
studies.83, 86
Markov modeling and related techniques are beneficial for simulating future
outcomes, which extend beyond the time horizon of the study or trial. These models
typically use long-term cost-effectiveness measures, such as life-years saved or QALYs,
to estimate long-term impacts of smoking cessation on morbidity and/or mortality. This
technique can be used prospectively to provide justification for long-term investments in
interventions to achieve greater cessation. While this may not be of great importance to
health plans, which typically focus on short-term outcomes, it provides great value to
healthcare systems that finance the healthcare of a population over the lifetime.
Summary
Studies evaluating cost-effectiveness of moderate to intense smoking cessation
interventions may be underrepresented in this review. This is due in part to selection
criteria used. Requirement of pharmacotherapy and counseling caused several studies
involving pregnant smokers to be excluded. In addition, newer studies in smoking
cessation are analyzing alternative intervention contact methods (via computer, mail, or
telephone counseling/quit lines), which were not included. A significant number of costeffectiveness analyses conducted abroad were also excluded because they were published
in foreign languages. A broader body of literature in economic evaluation of smoking
cessation exists; many of these studies address alternative strategies: reimbursement of
smoking cessation treatments, tobacco taxation and anti-smoking policies and campaigns.
Still, this review provides a strong base for which STEP results can be compared.
Among the studies reviewed here, only three were conducted in the United States
and none of them comply with current recommendations outlined by the Panel. Given the
expanded use of economic evaluations in healthcare to inform financing and clinical
guidelines, studies must prove methodologically sound, clinically oriented, and policy
relevant. The recent growth of cost-effectiveness literature in smoking cessation indicates
wider acceptance of economic evaluation in the field. Conversely, as the characteristics
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of the smoking population changes (more established, recalcitrant smokers), researchers
will need to place increased emphasis on conducting and evaluating more moderate to
intense interventions.91 Smokers today are more likely to be low-income, educated at a
high school level or less, and minority. Without focused intervention in these vulnerable
populations, where a paucity of research already exists, disparities will continue to
persist.
Conducting an economic evaluation for STEP is necessary for several reasons.
First, it will build on literature evaluating cost-effectiveness of newer smoking cessation
interventions. Fiore and colleagues have proposed further study of stepped care in
smoking cessation; as yet, no formal recommendation for this or other tailored
approaches has been made.33 In addition, conducting cost-effectiveness alongside a
stepped care study is feasible and generally encouraged.79 Second, this study will adhere
to standards recommended by the Panel. Economic evaluations conducted in the United
States have consistently lacked a methodological standard, while the United Kingdom
and other countries adhere to and enforce use of a single standard of conduct. Lastly, this
evaluation is needed to justify future funding of tobacco control efforts, which must focus
on the smoking population which remains. The underlying study is comprised of lowincome, minority smokers for which more research is needed to establish effectiveness
and cost-effectiveness.
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CHAPTER 3: METHODS
Data Collection
Data for the study was collected as part of the original research intervention,
STEP. Data was collected at each visit from research participants via questionnaires and
patient chart records. The data captured smoking status, nicotine dependency, and other
statistics relevant to the study. Data from forms and charts were checked for
completeness and accuracy before being entered into the system. Validation checks were
run periodically to identify data errors. More specific details regarding data collection
and management are described elsewhere. Data collected through June 2009 were
cleaned and converted into a de-identified dataset for use in the cost-effectiveness
analysis. Although requirements for human subjects training have been satisfied, the
original dataset with patient identifiers was not accessed to avoid unwarranted
identification of participants. Appropriate security measures were taken to ensure that
data and related components were not breached.
Sample Size
A total of 406 participants from University of Tennessee Health Science Center
(Memphis, Tennessee) and Mayo Clinic (Rochester, Minnesota) were enrolled in the
smoking cessation study. As of June 2009, data for 319 completers were available for
analysis; this included the full sample from Mayo Clinic (n=136) and a significant
portion from UTHSC (183 of 270). Descriptive analyses were conducted to test the
statistical equivalence of completers and the remaining UTHSC sample. The results of
this analysis, shown in Table 3-1, reveal no differences in most factors. Estimates for
both cost-effectiveness analysis and simulation of future events were based on completers
at June 2009.
Conducting Cost-Effectiveness Analysis
As mentioned earlier, methodological standards for conducting cost-effectiveness
analyses in medicine and health were released in 1996 by the U.S. Public Health
Service’s Panel on Cost-Effectiveness in Health and Medicine.80 These standards have
grounded the methodology of this analysis, using a reference case method. The Panel
requires that cost-effectiveness analyses be conducted from the societal perspective,
including all costs associated with disease and treatment as well as future costs averted by
intervention. Additionally, the standards require use of cost-utility analysis (a specific
subtype of cost-effectiveness analysis), where health-related quality of life measures are
incorporating into cost-effectiveness ratios to produce a dollar cost per quality-adjusted
life year (QALY) gained. In STEP, no measures are collected to evaluate health-related
quality of life; further, the time horizon of the study (two years) is not adequate enough to
assess long-term impacts of cessation on costs and quantity/quality of life. For purposes
of this study, two analyses were conducted. First, the cost-effectiveness analysis of the
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Table 3-1. Characteristics of Completers versus Remaining Participants

Variable
Age, mean (SD)

UTHSC
Stepped Stepped
care
care
Repeat
sample
others
sample
(n=85)
(n=43)
(n=98)
44.1
44.7
45.1
(9.7)
(11.1)
(11.4)

Gender, n (%)
Male
Female
Race/ethnicity,
n (%)
NHW
NHB
OTH
Fagerstrom
score, mean
(SD)
CES-D score,
mean (SD)
CPD, mean
(SD)
CO, mean (SD)

Mayo Clinic
Repeat
others
(n=44)
46.4
(9.7)

Repeat
(n=70)
40.8
(10.7)

Stepped
care
(n=66)
40.4
(12.6)

39 (46)
46 (54)

16 (37)
27 (63)

43 (44)
55 (56)

39 (46)
46 (54)

32 (46)
38 (54)

37 (56)
29 (44)

40 (47)
45 (53)
0 (0)
5.91
(2.2)

18 (42)
25 (58)
0 (0)
5.11
(2.2)

54 (55)
43 (44)
1 (1)
5.57
(2.3)

40 (47)
45 (53)
0 (0)
5.68
(2.3)

65 (93)
4 (6)
1 (1)
5.44
(1.7)

59 (89)
1 (2)
5 (9)
5.39
(2.2)

10.07
(6.9)
23.0
(11.6)
23.51
(11.6)

6.84
(6.6)a
20.7
(8.8)
19.36
(8.4)c

9.88
(7.3)
23.7
(11.2)
23.36
(12.2)

8.09
(6.1)
23.5
(9.5)
18.74
(9.9)d

8.70
(6.1)
21.3
(8.4)
22.70
(9.8)

6.35
(5.8)b
20.5
(7.3)
22.22
(10.9)

Note: Differences across UTHSC groups are noted by superscript letters.
a

Significant at p=0.01
Significant at p=0.02
c
Significant at p=0.01
d
Significant at p=0.03
b

Abbreviations: CES-D: Center for Epidemiologic Studies Depression Scale; CO: carbon
monoxide, CPD: cigarettes per day, NHB: non-Hispanic black, NHW: non-Hispanic
white, OTH: other race, SD: standard deviation.
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STEP study was conducted from an institutional perspective. Next, the simulation of
future outcomes, which extends cost-effectiveness to the lifetime, encompassed a societal
perspective. This exception is accepted by Gold; evaluation of cost-effectiveness from
multiple perspectives is permitted, as long as one (the reference case analysis) is
societal.80
Study Design
A schematic of the STEP study is illustrated in Figure 3-1. As mentioned
previously, patients received up to three opportunities to receive combined
pharmacological and behavioral treatment. As baseline, eligible patients were
randomized to stepped care or repeat care arms. They then received initial treatment
(nicotine patch and one counseling session). Patients returned at six months, quit status
was assessed, and appropriate treatment assigned. For example, a stepped care patient
who relapsed at the six-month visit was stepped up to bupropion and four counseling
sessions; a repeat care patient who relapsed at six months received nicotine patch therapy
and one counseling session again. Patients who quit successfully did not receive
intervention. A similar strategy was used for patients returning at twelve months. Patients
could not receive treatment beyond the twelve month visit; quit status was assessed at 18
months and at final follow-up (24 months).
Calculation of Research Costs
Since analysis took place alongside a research study, only direct medical and
treatment costs borne by the research study were considered. Costs included were for
pharmacotherapy, treatment and follow-up visits, counseling sessions, telephone followup, and participant time lost in treatment. Any outside costs borne by patients to achieve
and/or maintain cessation were not included. Indirect administrative costs were also
excluded, as these data were not made available. Costs for pharmacotherapy reflect
lowest retail costs; these were adjusted as necessary to reflect base year pricing.
Treatment and follow-up visit costs were calculated using average visit time multiplied
by the hourly wage(s) of the research personnel involved. Supplies used during the
treatment visit were not considered (i.e. urinalysis and cotinine validation), as they were
minimal and unlikely to differ between study arms. Costs of counseling were calculated
by multiplying the research nurse’s hourly wage by the amount of time spent counseling.
Telephone follow-up costs were calculated using time spent making telephone follow-up
calls multiplied by the hourly wage of research personnel. Participants received
reimbursement at each treatment and follow-up visit; these costs were summed to
represent time lost in treatment. A separate cost for missed visits was assigned. Labor
costs were sourced from the Bureau of Labor Statistics, using 2006 median estimates for
registered nurse and medical assistant titles.92 Details of the cost calculations are outlined
in Table 3-2.
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Figure 3-1. STEP Study Schematic
Note: Shaded areas denote study periods (i.e. baseline, 6-month visit, etc.).
Abbreviations: M: months; Maintain: maintenance phase; Step 1: nicotine patch plus 1
counseling session; Step 2: bupropion plus 4 counseling sessions; Step 3: nicotine patch
and gum plus 6 counseling sessions.
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Table 3-2. Cost Calculations for STEP CEA
Unit
cost

Resource
Pharmacotherapy
Patch (Steps 1-3)

Units

Gum (pieces)

1680

$0.25

123

$1.17

Patch + gum
Bupropion (150 mg)
Clinic visit
Technician time (hrs)
Nurse time (hrs)

1 $85.97

Total

$85.97 6 weeks Habitrol (2 weeks @
21, 14, 7mg)
$424.84 Nicorette gum (12 ppd, 4
weeks; 24 ppd, 8 weeks)
$510.81
$143.47 AWP, 2006 RedBook

0.417 $12.64

$5.27 Technician costs to take labs,
verify CO levels, height/weight
(25 minutes)
$9.18 Nurse time for patient
assessment (20 minutes)
$27.54 Counsel cost/session
(Counselor: Research nurse)
$25.00 Patient incentive for
participation
$3.16 Staff time spent to assess quit
status, provide support (15
minutes)
$70.15 Total visit cost: Items 2a-2d

0.333 $27.54

Counselor time (hrs)

1 $27.54

Patient time lost in
treatment
Telephone follow-up
(@7 wk)

1 $25.00
0.25 $12.64

Total visit
Step cost
Patch
Bupropion
Patch + gum
Recycle cost (Patch)

Notes/Source

$156.12 Patch + Clinic visit
$334.16 Bupropion + Clinic visit + 3
additional counsel + 12 phone
calls
$728.14 Patch + gum + Clinic visit + 5
additional counsel + 3 phone
calls
$156.12 Patch + Clinic visit

Missed visit
Maintain

$9.48 Follow-up phone calls
$45.77 Clinic visit + summary of
progress (15 minute assessment)
$42.61 Clinic visit + summary of
progress (15 minute assessment)

Follow-up

Note: Costs not available for 2006 were adjusted accordingly, using the Consumer Price
Index.
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Measures and Validation of Cessation
The underlying intervention relied on self-report of abstinence, with expired
carbon monoxide readings as an auxiliary mechanism for validating point-prevalent
cessation. Expired carbon monoxide measurements are captured by a small machine
connected to a small disposable tube in which a participant exhales. This was performed
at baseline and at each follow-up. If a participant reported abstinence but yielded an
expired carbon monoxide reading beyond 10 parts-per-million (ppm), salivary cotinine
measures were collected. Cotinine is a specific major metabolite of nicotine that can be
detected in body fluids for 48 to 72 hours. It is considered the best biomarker for
validating cessation. A self-reported abstainer with an unsatisfactory expired carbon
monoxide reading (>10 ppm) and salivary cotinine level of 15 ng/mL or above was
considered a continued smoker. This scenario is generally uncommon, as self-reports
tend to be accurate with low false-negative rates.89
Point-prevalent abstinence was used throughout the study to determine treatment
paths. As mentioned above, point-prevalent abstinence was biochemically validated.
Unacceptable carbon monoxide and salivary cotinine measures, despite self-report of
abstinence, were considered treatment failure at each follow-up. Otherwise, failure was
defined as smoking seven consecutive days or at least once a week on two consecutive
weeks after the quit date, in accordance with recommendations.93 Continuous abstinence
was used as the primary measure for end-of study-cessation; because it accounted for
lapses, it could not be biochemically verified and was obtained via self-report. Pointprevalence abstinence was used as a secondary end-of-study measure, as it was captured
at each follow-up and used as a determinant of treatment. These measures were used in
cost-effectiveness analysis to determine number of quitters in each treatment arm.
Patients with complete observations were allocated costs on the basis of quit
status at each visit, as it determined the treatment received. Patients missing data at any
treatment or follow-up visit were assigned a cost equivalent to three follow-up calls. This
cost represented time spent following up with patients who had missed a visit to
encourage continued participation in the trial. End of study abstinence was determined by
smoking status at the final follow-up visit. Patients missing data for this visit were
assumed to be smoking at study end.
Calculation of Cost-Effectiveness
Considering the setting of the research study, the outcome of interest is a ratio of
incremental cost per additional cessation achieved by stepped care relative to repeat care.
The numerator of this ratio is the difference in costs in the stepped care arm relative to
the repeat care arm, whereas the denominator captures the difference in the number of
quitters. The ratio of cost differences to effect differences yields incremental costeffectiveness, or the cost to achieve one additional unit of effect. Whether the study is
considered ‘cost-effective’ depends on both the ICER and a predetermined threshold. In
the United States, no standard threshold for cost-effectiveness exists. For the purposes of
this research, a threshold was set at $10,000/quit, to account for differences in treatment
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time between short-term studies reviewed and STEP. Short-term studies were at most
$5,067 per quit; a threshold of twice this amount was considered reasonable for
establishing cost-effectiveness of STEP. A separate cost-effectiveness calculation as
made for each type of quit (point-prevalence, continuous), as explained previously. All
figures were adjusted to 2009 U.S. dollars.
Discounting
Time gaps between costs of intervention and realization of benefits exists when
valuating cost-effectiveness of smoking cessation interventions. Typically the time
horizon of the trial is too short to realize long-term outcomes of treatment. Discounting
becomes necessary to calculate the present value of costs incurred and benefits achieved
beyond the base year. As mentioned previously, Gold and colleagues recommend a 3%
discount rate be applied to balance these differences in time.80 For this portion of the
economic evaluation, discounting was applied only to costs incurred during year two of
the study. Effects (number of quits) were not discounted.
Simulating Future Health Outcomes
The simulation model being used in the long-term analysis of smoking cessation
considered lifetime effects of cessation on smoking-related morbidity and mortality and
was adapted from Hoogenveen and Hurley.94, 95 Figure 3-2 depicts changes in the disease
pathway that occurs as a result of cessation. In general, continued smoking leads to
increased risk of morbidity and mortality resulting from smoking-related illnesses. For
the purposes of this analysis, ischemic heart disease (including heart attack),
cerebrovascular disease (including stroke), emphysema, lung cancer are modeled. Once
tobacco-related disease is present, patients suffer decreased quality of life, increased
healthcare expenditures and mortality risk. With timely intervention, a portion of current
smokers will quit permanently. As a result, smoking-related disease can be averted, thus
minimizing loss of quality of life, excess expenditures due to disease, and premature
death.
Model Structure and Parameters
In order to model changes in smoking-related morbidity and mortality due to
successful smoking cessation, a microsimulation model was constructed using TreeAge
Pro Suite 2009 (TreeAge Software Inc., Williamstown, MA). Using TreeAge, simple or
complex disease or decision processes can be modeled. A simulation model was chosen
over a traditional Markov type to account for patient-level characteristics (i.e. gender,
race, age, and smoking status) that would impact transitions through the model.
Figure 3-3 illustrates the simulation model used for long-term cost-effectiveness
analysis. The model includes five health states; state numbers indicate progression of
disease while state letters denote smoking status. Patients enter the model in state 1A or
1B, based on end-of-study smoking status. (The model assumes that, at entry, no one has
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Figure 3-2. Change in Disease Pathway with Successful Cessation
Sources: Hoogenveen RT, van Baal PH, Boshuizen HC, Feenstra TL. Dynamic effects of
smoking cessation on disease incidence, mortality and quality of life: The role of time
since cessation. Cost Eff Resour Alloc. 2008 January 11; 6:1.94
Hurley SF, Matthews JP. The Quit Benefits Model: a Markov model for assessing the
health benefits and health care cost savings of quitting smoking. Cost Eff Resour Alloc.
2007 January 23; 5:2.95
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Figure 3-3. Long-Term Outcomes Simulation Model
Note: Stages 2A and 2B were partially collapsed to allow text to be readable at 100%.
Stages 1A and 2A are identical in structure, as are stages 1B and 2B.
Abbreviations: CBD: cerebrovascular disease, CSND: current smoker no disease,
CSWD: current smoker with disease, EMP: emphysema, FSND: former smoker no
disease, FSWD: former smoker with disease, IHD: ischemic heart disease, LC: lung
cancer.
Source: TreeAge Pro Suite 2009 (TreeAge Software Inc., Williamstown, MA).
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heart disease, COPD, or lung cancer.) These states are somewhat parallel, because until
disease is acquired, smoking status will influence movement across them. However,
patients in state 1B (current smoker, no disease) are more likely than those in 1A to either
acquire disease or die, progressing to the next appropriate state (current smoker with
disease or death). Only forward movement is allowed in the model; once a patient has
disease, he cannot move backward to a non-diseased state. Likewise, once a patient
moves to state 3 (death), they remain in that state until the model terminates. During each
cycle, changes in smoking status, morbidity and mortality risks, annual treatment costs,
and rewards (life-years or QALYs) are calculated. At the end of each cycle, survival,
smoking and disease statuses determined state transitions.
Smoking-Related Mortality
At the beginning of each cycle, mortality risk was assessed. During the first cycle,
mortality risk was conditional on race-, gender-, and age-specific risk of death from other
causes (not including death from smoking-related diseases being modeled). In subsequent
cycles, mortality risk was contingent upon race, age, gender, risk of background death,
and presence of smoking-related diseases. Because death can occur at any time during a
cycle (year), it was expected that patients dying during a cycle would incur some
healthcare costs. As a result, the model assesses one-half of the expenditures that would
have been incurred without changes in disease or smoking status. So, if a patient entered
the cycle as a former smoker with no disease, one-half the annual expenditures for a
former smoker of his current age without disease would be assessed at death. Mortality
rates were sourced from the 2006 Compressed Mortality File using CDC WONDER, an
interactive database tool that houses public-use data on mortality, cancer incidence, HIV
and AIDS, etc.96 The system was queried first for deaths from all causes, and separately
for any deaths with cerebrovascular disease, ischemic heart disease, lung cancer, or
emphysema as an underlying cause. Here, underlying cause identifies the disease or
injury which initiated the train of events leading directly to death and would not include
deaths due to injury among persons with the above-listed disease. Multiple-decrement life
tables were created for each race-gender group, rendering age-specific probabilities of
mortality from background causes and presence of smoking-related diseases, shown in
Table 3-3. Life tables methods were sourced from Anderson.97 A patient’s risk of death
was expressed as a summed probability of mortality (MR) conditional on race, age,
gender (RAG) and presence of smoking-related diseases (1=present, 0=absent), as shown
in Equation 3-1:
MR(Background causes) = MR(All causes|RAG) – MR(Lung cancer|RAG) – MR(Emphysema|RAG) –
MR(Cerebrovascular|RAG) – MR(Ischemic|RAG)
MR(Patient) = MR(Background causes|RAG) + MR(Lung cancer|RAG)*(1/0) + MR(Emphysema|RAG)*(1/0) +
MR(Cerebrovascular|RAG)*(1/0) + MR(Ischemic|RAG)*(1/0)
(Eq 3-1)
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Table 3-3. Mortality Rates by Age, Race, and Gender
NHW
Cause Age group
BC
15-24 years
25-34 years
35-44 years
45-54 years
55-64 years
65-74 years
75-84 years
85+ years
IHD
15-24 years
25-34 years
35-44 years
45-54 years
55-64 years
65-74 years
75-84 years
85+ years
CBD 15-24 years
25-34 years
35-44 years
45-54 years
55-64 years
65-74 years
75-84 years
85+ years
EMP 15-24 years
25-34 years
35-44 years
45-54 years
55-64 years
65-74 years
75-84 years
85+ years
LC
15-24 years
25-34 years
35-44 years
45-54 years
55-64 years

M
0.0183
0.0202
0.0367
0.0688
0.0978
0.1644
0.3677
0.3074
0.0001
0.0006
0.0046
0.0168
0.0332
0.0570
0.1314
0.1183
0.0001
0.0002
0.0009
0.0025
0.0050
0.0124
0.0375
0.0358
0.0000
0.0000
0.0000
0.0002
0.0011
0.0032
0.0057
0.0026
0.0000
0.0001
0.0010
0.0062
0.0187

NHB

F
0.0064
0.0080
0.0195
0.0391
0.0635
0.1135
0.2858
0.2516
0.0000
0.0002
0.0012
0.0042
0.0106
0.0252
0.0801
0.0910
0.0001
0.0002
0.0007
0.0018
0.0035
0.0092
0.0358
0.0382
0.0000
0.0000
0.0000
0.0002
0.0008
0.0022
0.0039
0.0013
0.0000
0.0000
0.0009
0.0042
0.0116
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M
0.0377
0.0478
0.0725
0.1378
0.1729
0.2457
0.4208
0.3229
0.0003
0.0013
0.0067
0.0270
0.0492
0.0787
0.1306
0.1027
0.0002
0.0006
0.0027
0.0089
0.0152
0.0256
0.0482
0.0354
0.0000
0.0000
0.0001
0.0005
0.0011
0.0023
0.0038
0.0021
0.0000
0.0001
0.0018
0.0120
0.0281

F
0.0123
0.0226
0.0513
0.0942
0.1184
0.1774
0.3304
0.2539
0.0001
0.0006
0.0036
0.0127
0.0249
0.0481
0.1030
0.0897
0.0001
0.0007
0.0027
0.0073
0.0099
0.0192
0.0473
0.0385
0.0000
0.0000
0.0000
0.0002
0.0005
0.0009
0.0016
0.0005
0.0000
0.0001
0.0015
0.0065
0.0132

OTH
M
0.0343
0.0389
0.0587
0.0961
0.1320
0.1913
0.3641
0.3048
0.0001
0.0017
0.0063
0.0208
0.0383
0.0642
0.1250
0.1140
0.0001
0.0003
0.0021
0.0082
0.0113
0.0229
0.0536
0.0449
0.0000
0.0000
0.0002
0.0001
0.0007
0.0023
0.0041
0.0018
0.0000
0.0003
0.0022
0.0080
0.0182

F
0.0164
0.0232
0.0419
0.0772
0.1077
0.1737
0.3286
0.2406
0.0002
0.0002
0.0013
0.0061
0.0145
0.0399
0.0979
0.0941
0.0003
0.0005
0.0020
0.0056
0.0100
0.0211
0.0591
0.0459
0.0000
0.0000
0.0000
0.0002
0.0005
0.0011
0.0014
0.0007
0.0000
0.0001
0.0011
0.0060
0.0122

Table 3-3. (continued)
NHW
Cause Age group
LC
65-74 years
75-84 years
85+ years

M
0.0359
0.0482
0.0150

NHB

F
0.0212
0.0274
0.0066

M
0.0425
0.0522
0.0160

F
0.0209
0.0247
0.0059

OTH
M
0.0380
0.0483
0.0136

F
0.0250
0.0263
0.0072

Notes: Estimates were truncated to the fourth decimal place to fit the page.
Deaths from diseases were identified by ICD-10 codes or groups: Ischemic heart disease
(ICD-10: I20-I25), Cerebrovascular disease (ICD-10: GR113-070), Emphysema (ICD10: GR113-084), Lung cancer (ICD-10: GR113-027).
Abbreviations: BC: background causes, CBD: cerebrovascular disease, EMP:
emphysema, F: female, IHD: ischemic heart disease, LC: lung cancer, M: male, NHB:
non-Hispanic black, NHW: non-Hispanic white, OTH: other race.
Source: Centers for Disease Control and Prevention, National Center for Health
Statistics. Compressed Mortality File 1999-2006. CDC WONDER Online Database,
compiled from Compressed Mortality File 1999-2006 Series 20 No. 2L, 2009. Accessed
at http://wonder.cdc.gov/cmf-icd10.html on August 19, 2009.99
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Smoking-Related Disease
For patients surviving in a cycle, risk of acquiring smoking-related disease was
assessed. As mentioned previously, patients’ risk of developing lung cancer, emphysema,
cerebrovascular disease, and ischemic heart disease was modeled. Data from the National
Health and Nutrition Examination Survey (NHANES) for years 2001-2006 were pooled
to estimate incidence of the above-mentioned smoking-related diseases.98 Data from the
smoking, demographic, and medical conditions modules for the 2001-02, 2003-04, and
2005-06 NHANES cycles were merged by cycle, then resorted by SDMVSTRA and
SDMVPSU variables and combined into a single dataset. The dataset was queried to
identify incident cases of the four smoking-related diseases among never, former, current
smokers by race, gender, and age (18-34 years, 35-64 years, and 65 years and above).
Prevalent cases of ischemic heart disease were identified by a positive response to one of
two questions (positive diagnosis of coronary heart disease or previous heart attack).
Prevalent cases of stroke, emphysema, and lung cancer were identified similarly, denoted
by positive response to questions regarding physician diagnosis of disease. Time since
diagnosis for smoking-related diseases was calculated by subtracting the survey
respondent’s age at diagnosis from age when interviewed. Prevalent cases with a time to
diagnosis of 0 and half of cases with a time to diagnosis of 1 were identified as incident
cases in the absence of specific dates of birth, diagnosis, and interview. Incidence
estimates were calculated using larger age group intervals than before to generate more
reliable estimates across race and smoking status. Several studies indicate that risk of
cardiovascular disease among former smokers and never smokers is equal after about 10
years, while rates of emphysema and lung cancer remain elevated among former
smokers. Since data were not robust enough to evaluate this trend, the appropriate
incidence probabilities for never smokers were re- assigned to former smokers achieving
abstinence beyond 10 years. In certain cases, incident cases were too low to provided
estimates for specified cage groups and were combined to provide a single estimate for
incidence risk. Table 3-4 summarizes the incidence probabilities generated for analysis.
Cessation and Relapse
Risk of relapse remains for quitters, although this probability decreases as a
function of time spent abstinent. The longer a quitter remains a former smoker, the less
likely they are to relapse in the future. To account for time since cessation, a tracker
variable was created in TreeAge to count the number of continuous cycles spent in as a
former smoker. The number of continuous cycles coincided with number of years of
abstinence. The model assigned a probability of relapse, using published relapse rates for
two to four years post cessation,100, 101 and interpolated rates for years 5 and beyond.
Current smokers who made a successful quit attempt during a cycle transitioned to a
former smoker, while those who were unsuccessful remained as current smokers.
Likewise, a former smoker that relapsed during a cycle would become a current smoker
in the next, while those who remained abstinent would continue the next cycle as a
former smoker. Here, the model assumed that any future quit attempts would be unaided,
since results from a recent NHIS survey suggested that most smokers quit in this fashion.
So, the model assigned a quit probability equivalent to 12 month abstinence for an
unaided quit attempt.102
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Table 3-4. Incidence Rates for Smoking-Related Diseases

Disease Status Age group
IHD
Current 18-34 years
35-64 years
65+ years
Former 18-34 years
35-64 years
65+ years
Never
18-34 years
35-64 years
65+ years
CBD
Current 18-34 years
35-64 years
65+ years
Former 18-34 years
35-64 years
65+ years
Never
18-34 years
35-64 years
65+ years
EMP
Current 18-34 years
35-64 years
65+ years
Former 18-34 years
35-64 years
65+ years
Never
18-34 years
35-64 years
65+ years
LC
Current 18-34 years
35-64 years
65+ years
Former 18-34 years
35-64 years
65+ years
Never
18-34 years
35-64 years
65+ years

NHW
E
SE
0.000 0.000
0.010 0.004
0.005 0.004
0.000 0.000
0.011 0.004
0.029 0.004
0.000 0.000
0.008 0.002
0.026 0.005
0.000 0.000
0.005 0.002
0.006 0.005
0.000 0.000
0.003 0.000
0.018 0.004
0.000 0.000
0.002 0.001
0.019 0.004
0.004 0.003
0.008 0.002
0.030 0.014
0.000 0.000
0.002 0.001
0.011 0.004
0.000 0.000
0.001 0.001
0.002 0.001
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.002 0.001
0.008 0.003
0.000 0.000
0.000 0.000
0.000 0.000
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NHB
E
SE
0.000 0.000
0.010 0.005
0.010 0.005
0.000 0.000
0.015 0.008
0.022 0.007
0.002 0.002
0.003 0.002
0.029 0.011
0.000 0.000
0.002 0.002
0.009 0.010
0.000 0.000
0.006 0.004
0.035 0.017
0.000 0.000
0.008 0.003
0.040 0.013
0.000 0.000
0.001 0.001
0.001 0.001
0.000 0.000
0.003 0.003
0.006 0.006
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.049 0.034
0.005 0.002
0.005 0.002
0.000 0.000
0.000 0.000
0.000 0.000

OTH
E
SE
0.003 0.003
0.007 0.005
0.005 0.004
0.000 0.000
0.010 0.005
0.018 0.014
0.000 0.000
0.002 0.001
0.026 0.017
0.009 0.007
0.010 0.007
0.008 0.003
0.000 0.000
0.003 0.002
0.016 0.007
0.000 0.000
0.006 0.003
0.012 0.007
0.005 0.005
0.015 0.010
0.003 0.003
0.000 0.000
0.000 0.000
0.003 0.004
0.000 0.000
0.001 0.001
0.002 0.002
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000

Table 3-4. (continued)
Note: Estimates were truncated to the third decimal place to fit on the page. In certain
cases, no incidences of smoking-related diseases were reported; so rates were set to zero.
Abbreviations: CBD: cerebrovascular disease, EMP: emphysema, E: estimate, IHD:
ischemic heart disease, LC: lung cancer, M: male, NHB: non-Hispanic black, NHW: nonHispanic white, OTH: other race, SE: standard error.
Source: Centers for Disease Control and Prevention (CDC). National Center for Health
Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville,
MD: U.S. Department of Health and Human Services, Centers for Disease Control and
Prevention, 2000-2006. Accessed online at: http://www.cdc.gov/nchs/nhanes.htm on
August 19, 2009.98
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Healthcare Costs
Data from the 2006 Medical Expenditure Panel Survey (MEPS) were used to
calculate relevant annual healthcare expenditures for patients dependent on age and
presence of smoking-related diseases.103 Household component and medical conditions
files were sorted by an identifier variable, DUPERSID, and merged to provide data on
health expenditures resulting from smoking-related diseases. Medical conditions were
identified by three-digit ICD-9 diagnosis codes and broader Clinical Classifications
System (CCS) categories, which combine ICD-9 codes into more clinically relevant
classes for easier analysis. CCS codes were used to denote observations recording
expenditures due to lung cancer (CCS: 19), emphysema (CCS: 127), ischemic heart
(CCS: 100,101) and cerebrovascular diseases (CCS: 109-113). The total expenditure
variable, TOTEXP06, was fit to a regression equation, adjusting for age, gender, smoking
status, and presence of the four smoking-related diseases. From the regression equation,
gender- and age group-specific total expenditure and excess cost estimates for each
disease were calculated.
Quality-Adjusted Life Years (QALYs)
Health-related quality of life (HRQL) scores were also estimated from the MEPS
dataset used to calculate annual healthcare costs.103 In MEPS, several measures of health
status are collected annually, including the Short Form-12 (SF-12) health survey. Despite
its wide acceptance and application in health state evaluation, the SF-12 is limited in its
ability to provide only HRQL measures. It cannot rate patient preferences for specific
health states. Gold and colleagues recommend use of multi-attribute health status
classification systems (MAHSCS), which use time trade-off or standard gamble
techniques to elicit valuations of HRQL and preferences for other health states.79 These
preferences are converted into utility scores that can be used in cost-effectiveness
analysis. In the absence of these measures, mapping methods have been utilized to
approximate MAHSCS scores from other health status surveys. Sullivan and Ghushchyan
developed and validated a mapping algorithm to estimate EQ-5D scores from SF-12
measures using scores collected previously in MEPS.104 This algorithm was applied to
approximate EQ-5D scores from the SF-12 measures. In addition, these values were
modeled in ordinary least squares (OLS) regression, controlling for CCS codes,
demographic variables (age, gender), smoking status, and survey weights to generate
coefficients representing decrement(s) in utility resulting from smoking and smokingrelated disease(s). Table 3-5 illustrates age-specific annual healthcare costs and utility
weights used in analysis. Table 3-6 displays regression coefficients used to estimate
changes in annual costs and utilities due to smoking and smoking-related diseases.
Calculation of Cost-Effectiveness
Considering a societal perspective, the simulation model produced long-term costeffectiveness of STEP or the ratio of lifetime costs and effects among patients after
intervention in the study. TreeAge models were rerun assuming that all participants were
smokers to determine changes in lifetime healthcare costs, cases of smoking-related
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Table 3-5. Annual Healthcare Costs and Utilities Estimates
Costs

Utilitiesa

Gender
Female

Age group
18-24 years
25-34 years
35-44 years
45-54 years
55-64 years
65-74 years
75-84 years
85+ years

AACb
$1,383.27
$2,694.59
$4,005.91
$5,317.23
$6,628.54
$7,939.86
$9,251.18
$10,562.49

SE
361.95
412.36
462.77
513.19
563.60
614.01
664.42
714.83

AAUc
0.9755
0.9531
0.9307
0.9084
0.8860
0.8637
0.8413
0.8189

SE
0.004
0.005
0.006
0.006
0.007
0.007
0.008
0.008

Male

18-24 years
25-34 years
35-44 years
45-54 years
55-64 years
65-74 years
75-84 years
85+ years

$589.12
$1,900.44
$3,211.75
$4,523.07
$5,834.39
$7,145.70
$8,457.02
$9,768.34

544.36
594.77
645.18
695.59
746.00
796.41
846.82
897.23

0.9912
0.9688
0.9465
0.9241
0.9017
0.8794
0.8570
0.8346

0.006
0.007
0.007
0.008
0.008
0.009
0.009
0.010

Note: Estimates listed approximate annual costs and HRQL utilities for former smokers
without disease.
a

A mapping algorithm used to approximate EQ-5D scores from SF-12: EQ-5D=
0.057867 + 0.010367*PCS42 + 0.00822*MCS42 - 0.000034*PCS42*MCS42 - 0.01067
b,c
Total healthcare costs and EQ-5D scores were adjusted for age, gender, smoking
status, and presence of smoking-related diseases
Abbreviations: AAC: adjusted average cost, AAU: adjusted average utility, SE: standard
error
Sources: Center for Financing, Access, and Cost Trends, Agency for Healthcare Research
and Quality. Medical Expenditure Panel Survey, 2006103
Sullivan PW, Ghushchyan V. Mapping the EQ-5D index from the SF-12: US general
population preferences in a nationally representative sample. Med Decis Making 2006
July-August; 26(4):401-9.104
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Table 3-6. Changes in Costs and Utilities with Smoking/SR Disease
Costs
Smoking/SR disease
Current smoker
Ischemic heart disease
Cerebrovascular disease
Emphysema
Lung cancer

a

Δ(AAC)
-$284.66
$4,533.64
$5,133.11
-$595.31
$6,171.13

Utilities
SE
191.84
1016.23
1192.85
268.29
3197.38

Δ(AAU)b
-0.03468
-0.04821
-0.06138
-0.00671
-0.12297

SE
0.002794
0.01296
0.016126
0.004633
0.029451

Note: Estimates listed represent increments/decrements to costs and utilities when
smoking and/or smoking-related disease is present.
a,b

Changes in costs, utilities expressed in natural units (dollars, QALYs).

Abbreviations: Δ(AAC): change in adjusted average cost, Δ(AAU): change in adjusted
average utility, SE: standard error, SR: smoking-related.
Source: Center for Financing, Access, and Cost Trends, Agency for Healthcare Research
and Quality. Medical Expenditure Panel Survey, 2006103
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disease, QALYs and survival due to successful cessation. The costs and effects yielded
were subtracted from costs and effects in the initial model to calculate a ratio of
incremental costs per quality-adjusted life-year (QALY) gained by successful cessation
relative to unsuccessful cessation. The method of cessation (via stepped care or repeat
care) is no longer of immediate importance; that successful cessation occurred is more
relevant for examining future outcomes. The numerator of this ratio is the difference in
future costs incurred by successful quitters relative to unsuccessful quitters, whereas the
denominator captures the difference in the number of QALYs gained. The ratio of cost
differences to effect differences yields incremental cost-effectiveness, or the cost to
achieve one additional unit of effect. All figures were expressed in year 2009 U.S.
dollars.
Discounting
As aforementioned, Gold and colleagues recommend a 3% discount rate to balance time
gaps between costs of intervention and realization of benefits.80 For the extended
economic evaluation, discounting was applied to costs incurred and QALYs gained
beyond the base year (2009).
Sensitivity Analysis
Certain model parameters were assigned lower and upper values to account for
uncertainty around the model estimates; these values were used in sensitivity analysis.
Parameters were set for unaided cessation, disease incidence, and mortality rates as well
as annual healthcare costs and utilities, using calculated 95% confidence interval values
or published ranges from the literature (unaided cessation). One-way and probabilistic
sensitivity analyses (PSA) were conducted to evaluate impact of changes in disease
incidence, mortality, unaided cessation, costs, and utilities on outcomes. A uniform
distribution was applied to parameter values to equally select a range between lower and
upper limit values. PSA generated average, minimum, maximum, and standard deviation
values for costs and effects for treatment and comparator groups. The results of the
original simulation were stored and re-run substituting discount rates of 0% and 5%.
Comparing Results to Cost-Effectiveness Literature
Results of short-term and long-term analyses were compared to studies reviewed
in Chapter 2 to determine where STEP analyses fall in terms of cost-effectiveness. Costeffectiveness of the STEP study was compared to other short-term studies using cost per
quit as a measure. Results of the future outcomes simulation were compared to long-term
studies, both U.S. and international, that measured cost per QALY.
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CHAPTER 4: RESULTS
Cost-Effectiveness: STEP Study
Characteristics of the STEP study sample are outlined in Table 4-1. Overall and
by site, study arms were statistically equivalent. One exception was in the Mayo sample;
a statistically significant difference in CES-D scores was observed. UTHSC participants
were older and more racially diverse; in addition, they had higher depression scale and
nicotine dependence scores, carbon monoxide readings, and smoked more cigarettes than
Mayo Clinic counterparts. Only age and race differences were statistically significant.
Study participation rates were relatively average; these details are noted in Table 4-2.
Nearly 65% of study participants attended all treatment and follow-up visits; another 9%
attended all but one visit. The majority of patients attending all sessions were from
UTHSC, with 87% of participants remaining active (versus 34% of Mayo patients)
throughout the study. Among Mayo patients, those randomized to stepped care attended
more sessions than patients assigned to repeat intervention. This trend was similar in the
UTHSC sample. Most STEP participants were available for final follow-up (n=229); the
remainder were assumed to be smoking. Point-prevalence abstinence was confirmed in
67 participants; 41 of these patients also reported continuous abstinence at end of study
follow-up. Among those quitting, all but five reported to each treatment and follow-up
visit.
Table 4-3 reports costs, effects, and cost-effectiveness estimates for the entire
sample and by site. Stepped intervention was more costly than repeat care in every
scenario. Mean costs (per patient) were $875.09, $617.09, and $1,075.40 for overall,
Mayo Clinic, and University of Tennessee Health Science Center (UTHSC) samples,
respectively. All figures are expressed in 2009 U.S. dollars. Repeat costs were $422.26,
$332.55, and $486.34 for the respective samples. Point-prevalence abstinence was
reported and validated among 20.5% (versus 22.6%) of stepped care patients overall;
among Mayo and UTHSC samples, 22.7% (versus 22.9%) and 18.8% (versus 22.5%)
reported quitting. Continuous abstinence was reported among 11.9% (versus 14.3%),
16.7% (versus 15.7%) and 8.2% (versus 13.3%) of stepped care patients overall, at Mayo,
and at UTHSC, respectively. Because effectiveness results favored repeated intervention
rather than stepped care, an ICER could not be calculated for the overall sample. Stepped
care was dominated by repeat care; it was more costly and less effective. Among Mayo
participants, stepped care was more costly and more effective, producing and incremental
cost effectiveness estimate of $29,640 (continuous) per quit. This trend was opposite
among patients at UTHSC, where repeat care was dominant.
Differences in effectiveness by gender are reported in Tables 4-4 and 4-5.
Overall, higher rates of point-prevalence and continuous abstinence were reported among
men. Nearly 27% of men in the repeat intervention achieved point-prevalence abstinence
at study end compared to only 19% of women. Quit rates among men and women in
stepped care were similar, at 20% and 21%, respectively. Continuous abstinence was
reported in 13% and 11% of men and women in the stepped care arm and in 19% and
11% of men and women in the repeat intervention. Stepped care costs for women (versus
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Table 4-1. Characteristics of STEP Study Sample

Variables
Age, mean
(SD)
Gender, n (%)
Male
Female
Race, n (%)
NHW
NHB
OTH
Fagerstrom,
mean (SD)
CES-D, mean
(SD)
CPD, mean
(SD)
CO, mean
(SD)

Overall
Stepped
Repeat
care
(n=167)
(n=151)
43.3
42.4
(11.3)
(11.1)

UTHSC (sample)
Stepped
Repeat
care
(n=98)
(n=85)
45.1
44.1
(11.4)
(9.7)

Mayo
Stepped
Repeat
care
(n=70)
(n=66)
40.8
40.4
(10.7)
(12.6)

75 (45)
93 (55)

76 (50)
75 (50)

43 (44)
55 (56)

39 (46)
46 (54)

32 (46)
38 (54)

37 (56)
29 (44)

119 (71)
47 (28)
2 (1)
5.52
(2.0)
9.39
(6.9)
22.7
(10.2)
22.12
(11.4)

99 (66)
46 (30)
5 (4)
5.68
(2.2)
8.44
(6.7)
21.9
(10.0)
21.80
(11.4)

54 (55)
43 (44)
1 (1)
5.57
(2.3)
9.88
(7.3)
23.7
(11.2)
23.36
(12.2)

40 (47)
45 (53)
0 (0)
5.91
(2.2)
10.07
(6.9)
23.0
(11.6)
23.51
(11.6)

65 (93)
4 (6)
1 (1)
5.44
(1.7)
8.70
(6.1)
21.3
(8.4)
22.70
(9.8)

59 (89)
1 (2)
5 (9)
5.39
(2.2)
6.35
(5.8)a
20.5
(7.3)
22.22
(10.9)

Note: UTHSC sample includes study completers as of May 31, 2009.
a

Statistically significant at p=0.03

Abbreviations: CO: carbon monoxide, CES-D: Centers for Epidemiologic Studies
Depression Scale, CPD: cigarettes per day (number), NHB: non-Hispanic black, NHW:
non-Hispanic white, OTH: other race, UTHSC: University of Tennessee Health Science
Center.
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Table 4-2. STEP Study Outcomes

Overall
A
S

Outcomes
Visits
attended
(%)
1
2
3
4
5
Total
Therapy
(%)
2
3
Quits, (%)
PPA
CA

R

47
16
(15) (11)
21
14
(7) (9)
16
6
(5) (4)
11
30
(9) (7)
205 104
(64) (69)
319 151

31
(18)
7 (4)

Participants
Mayo
S
R

UTHSC
S
R

Quitters
PPA CA
A
A

30
(43)
5 (7)

0 (0)

1 (0)

-

-

0 (0)

2 (2)

-

-

10
(6)
19
(12)
101
(60)
168

16
(24)
14
(21)
4
(6)
5
(8)
27
(41)
66

9
(13)
7
(10)
19
(27)
70

2 (2)

1 (1)

-

-

6
(7)
77
(91)
85

12
(12)
82
(84)
98

205 106
(64) (70)
179
89
(56) (59)

99
(59)
90
(54)

34
(52)
19
(29)

29
(41)
18
(26)

72
(73)
70
(71)

70
(82)
72
(84)

-

-

-

-

67
31
(21) (21)
41
18
(13) (12)

38
(23)
24
(14)

15
(23)
11
(17)

16
(23)
11
(16)

16
(19)

22
(22)
13
(12)

-

-

-

-

7 (8)

5
5
(7) (12)
62
36
(93) (88)
67
41

Abbreviations: A: all, CA: continuous abstinence, PPA: point-prevalence abstinence, R:
repeat care, S: stepped care, UTHSC: University of Tennessee Health Science Center.

52

Table 4-3. Cost-Effectiveness Results, Overall and by Site
All
Variable Arm
Costs
S
R
Diff
PPA
S
R
Diff
CA
S
R
Diff
ICER
PPA
CA

Mean
SE
$875.09 $36.60
$422.26 $10.53
$452.83
0.2053 0.033
0.2262 0.032
-0.0209
0.1192 0.027
0.1429 0.027
-0.0237
---

Mayo
Mean
SE
$617.09 $51.20
$332.55 $16.73
$284.54
0.2273 0.052
0.2286 0.051
-0.0013
0.1667 0.046
0.1571 0.044
0.0096
-$29,640

UTHSC
Mean
SE
$1,075.40 $39.76
$486.34 $9.14
$589.06
0.1882 0.043
0.2245 0.042
-0.0363
0.0824 0.030
0.1327 0.034
-0.0503
---

Note: Dotted lines denote scenarios in which stepped care was dominated by repeat care
(being more costly and less effective). Negative ICERs are not calculated.
Abbreviations: CA: continuous abstinence, Diff: difference in estimates (cost, effect),
ICER: incremental cost-effectiveness ratio, PPA: point-prevalence abstinence, R: repeat
intervention, S: stepped care intervention, SE: standard error, UTHSC: University of
Tennessee Health Science Center.
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Table 4-4. Cost-Effectiveness of STEP Study, Women
All
Variable
Costs
PPA
CA
ICER
PPA
CA

Arm
S
R
Diff
S
R
Diff
S
R
Diff

Mean
$837.75
$438.73
$399.02
0.2
0.1935
0.0065
0.1067
0.1075
-0.0008
$61,388
--

SE
$52.72
$14.08
0.047
0.041
0.036
0.032

Mayo
Mean
SE
$505.80 $68.80
$356.92 $24.69
$148.88
0.1724
0.071
0.2105
0.067
-0.0381
0.1379
0.065
0.1053
0.051
0.0326
-$4,567

UTHSC
Mean
SE
$1,047.00 $55.47
$495.26 $11.73
$551.74
0.2174
0.062
0.1818
0.053
0.0356
0.087
0.042
0.1091
0.042
-0.0221
$15,498
--

Note: Dotted lines denote scenarios in which stepped care was dominated by repeat care
(being more costly and less effective). Negative ICERs are not calculated.
Abbreviations: CA: continuous abstinence, Diff: difference in estimates (cost, effect),
ICER: incremental cost-effectiveness ratio, PPA: point-prevalence abstinence, R: repeat
intervention, S: stepped care intervention, SE: standard error, UTHSC: University of
Tennessee Health Science Center.
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Table 4-5. Cost-Effectiveness of STEP Study, Men
All
Variable
Costs
PPA
CA
ICER
PPA
CA

Arm
S
R
Diff
S
R
Diff
S
R
Diff

Mean
$911.94
$401.84
$510.10
0.2105
0.2667
-0.0562
0.1316
0.1867
-0.0551
---

SE
$50.80
$15.66
0.047
0.051
0.039
0.045

Mayo
Mean
SE
$704.32 $71.25
$303.62 $21.20
$400.70
0.2703
0.074
0.25
0.078
0.0203
0.1892
0.065
0.2188
0.074
-0.0296
$19,739
--

UTHSC
Mean
SE
$1,108.90 $57.13
$474.94 $14.43
$633.96
0.1538
0.059
0.2791
0.069
-0.1253
0.0769
0.043
0.1628
0.057
-0.0859
---

Note: Dotted lines denote scenarios in which stepped care was dominated by repeat care
(being more costly and less effective). Negative ICERs are not calculated.
Abbreviations: CA: continuous abstinence, Diff: difference in estimates (cost, effect),
ICER: incremental cost-effectiveness ratio, PPA: point-prevalence abstinence, R: repeat
intervention, S: rtepped care intervention, SE: standard error, UTHSC: University of
Tennessee Health Science Center.
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men) were $837.75 ($911.94), $505.80 ($704.32), and $1,047.00 ($1,108.90) overall, at
Mayo, and at UTHSC, in that order. Conversely, costs for repeat intervention were higher
for women, at $438.00 ($401.84), $356.92 ($303.62), and $495.26 ($474.94) among the
same groups. Stepped care was cost-effective for women achieving continuous
abstinence in the Mayo sample. Incremental cost-effectiveness in this population was
$4,567 per quit. Stepped care yielded incremental cost-effectiveness ratios for pointprevalence abstinence among all women, UTHSC women, and Mayo men; these
estimates were $61,388, $15,498, and $19,739 per quit for the respective populations.
Large cost and small effect differences yielded higher ICER estimates in these scenarios.
Racial/ethnic differences in costs and effectiveness were evident; these data are
presented in Table 4-6 and Table 4-7 for non-Hispanic white and ethnic minority
populations, respectively. Intervention costs, in either arm, were lower for non-Hispanic
whites versus ethnic minorities. Mean costs for stepped care and repeat interventions for
whites were $800.61 and $400.86, respectively; these costs among ethnic minorities were
$1,016.90 and $474.24, correspondingly. Similar differences in costs existed in the
UTHSC sample. Comparisons across race were not feasible in the Mayo sample, due to
underrepresentation of ethnic minorities. Non-Hispanic whites reported much higher rates
of cessation compared to ethnic minorities. Point-prevalence estimates were nearly twice
as high in both arms of the study overall among whites, at 24% versus 13% (stepped) and
26% versus 14% (repeat). Continuous abstinence was also consistently higher among
whites across study arms. Nearly 18% of whites using repeat intervention achieved
abstinence compared to only 6% of ethnic minorities. In stepped intervention, continuous
abstinence rates among whites and minorities were 15% and 6%, respectively.
Differences in effectiveness were even larger within the UTHSC sample. Pointprevalence abstinence was reported in 25% and 30% of white stepped and repeat
intervention patients, compared to 13% and 14% of ethnic minorities. Only 4% and 5%
of black stepped care and repeat intervention patients achieved continuous abstinence at
study-end; whites achieved rates of 13% and 20% in corresponding study arms. Stepped
care produced incremental cost-effectiveness ratios of $45,777 and $28,952 per quit in
the Mayo sample for point-prevalence and continuous abstinence.
Simulating Future Outcomes of Smoking Cessation
Results of the long-term simulation are reported in Table 4-8. In general,
encouraging smoking cessation through the STEP study was highly cost-effective. Mean
lifetime costs post-intervention were $49,025 per patient (95% CI: $6,320-$126,310) and
yielded 8.62 QALYs (95% CI: 0.46-20.64 QALYs). Average cost-effectiveness was
$6,530 per QALY (95% CI: $2,767-$19,441/QALY). Average age at model entry was 46
years; average age at death was 59 years. Figure 4-1 displays the distribution of costeffectiveness estimates for the simulation. Blue bars indicate probability of costeffectiveness below $2,000, $4,000, etc. For example, one cost-effectiveness estimate fell
below $2,000 per QALY; this is indicated in the 2000 bar. Fourteen estimates were
$2,000-$3,000, at a probability of 0.044; these are displayed in the next bar. The red bars
indicate where 10%, 50%, and 90% of cost-effectiveness estimates fell. Overall, 90% of
cost-effectiveness estimates were less than $9,000 per QALY.
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Table 4-6. Cost-Effectiveness of STEP Study, Non-Hispanic Whites
Variable
Costs
PPA
CA
ICER
PPA
CA

Arm
S
R
Diff
S
R
Diff
S
R
Diff

All
Mean
SE
800.61 45.134
400.86 12.807
399.75
0.2424 0.0433
0.2605 0.0404
-0.0181
0.1515 0.0362
0.1765 0.0351
-0.025

Mayo
Mean
SE
636.1 54.665
338.55 17.647
297.55
0.2373 0.0559
0.2308 0.0527
0.0065
0.1695 0.0493
0.1538 0.0451
0.0157

---

$45,777
$18,952

UTHSC
Mean
SE
1043.3 59.841
475.87
12.56
567.43
0.25 0.0693
0.2963 0.0627
-0.0463
0.125
0.053
0.2037 0.0553
-0.0787
---

Note: Dotted lines denote scenarios in which stepped care was dominated by repeat care
(being more costly and less effective). Negative ICERs are not calculated.
Abbreviations: CA: continuous abstinence, Diff: difference in estimates (cost, effect),
ICER: incremental cost-effectiveness ratio, PPA: point-prevalence abstinence, R: repeat
intervention, S: stepped care intervention, SE: standard error, UTHSC: University of
Tennessee Health Science Center.
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Table 4-7. Cost-Effectiveness of STEP Study, Ethnic Minorities

Variable
Costs
PPA
CA
ICER
PPA
CA

Arm
S
R
Diff
S
R
Diff
S
R
Diff

All
Mean
$1,016.90
$474.24
$542.66
0.1346
0.1429
-0.0083
0.0577
0.0612
-0.0035
---

Ethnic Minorities
UTHSC
SE
Mean
SE
$58.19
$1,104.00 $53.29
$16.27
$499.20 $13.20
$604.80
0.048
0.1333
0.051
0.051
0.1364
0.052
-0.0031
0.033
0.0444
0.031
0.035
0.0455
0.032
-0.0011
---

Note: Dotted lines denote scenarios in which stepped care was dominated by repeat care
(being more costly and less effective). Negative ICERs are not calculated.
Abbreviations: CA: continuous abstinence, Diff: difference in estimates (cost, effect),
ICER: incremental cost-effectiveness ratio, PPA: point-prevalence abstinence, R: repeat
intervention, S: stepped care intervention, SE: standard error, UTHSC: University of
Tennessee Health Science Center.
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Table 4-8. Cost-Effectiveness of Future Outcomes Simulation, Summary Statistics
Statistic
Mean
Std Dev
Minimum
2.50%
10%
Median
90%
97.50%
Maximum
Sum (n*mean)

Cost
$49,025
$33,491
$2,637
$6,320
$10,118
$42,740
$99,156
$126,310
$140,447
$15,638,951

Effect
Cost/Eff
8.62 Q
$6,530
5.75 Q
$3,535
0.44 Q
$1,401
0.46 Q
$2,767
1.36 Q
$3,639
8.07 Q
$5,976
16.58 Q
$8,686
20.64 Q $19,441
23.66 Q $29,236
2,750.62 Q
--

Start age
46.4
11.1
22
26
31
47
61
68
82
--

Death age
58.5
10.6
27
37
45
58
73
78
83
--

Note: Estimates at 2.5% and 97.5% denote the lower and upper bounds of the 95%
confidence interval.
Abbreviations: Cost/Eff: cost-effectiveness (average), Q; QALY, Std Dev: standard
deviation.

Figure 4-1. Distribution of Cost-Effectiveness Ratios
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Table 4-9 outlines outcomes of the original versus amended analyses. Differences
across analyses reflect benefit of cessation following the STEP intervention. In the
original simulation, 41 of 319 participants were abstinent at entry; of these, over half (24)
remained abstinent until death. Nearly 22% of participants were quitters at death. Costs in
the smoking simulation were $48,956 per person; this estimate was $69 lower than the
original simulation. Fewer QALYs were gained in the smoking simulation when
compared to the original (8.6 versus 8.62). Participants in the original simulation did not
live any longer than when in the smoking simulation. Age at death for each population
was 58.5 years. The smoking simulation yielded two more cases of cerebrovascular
disease, one more case each of emphysema and lung cancer, and two fewer cases of
ischemic heart disease than the original group. In all, this was a net decrease of two cases
of smoking-related disease. Incremental cost-effectiveness of successful STEP study
cessation was $3,450 per QALY gained.
Results of sensitivity analysis are reported in Table 4-10. These estimates account
for changes in natural quit, disease incidence, mortality, cost and utility parameters.
When considered individually, the largest drivers of incremental cost-effectiveness were
cerebrovascular disease incidence (248% increase), lung cancer and emphysema
incidence (155% increase for each) when set at their lower bounds and emphysema
incidence at its upper bound (164% increase). Individual parameters yielding more
favorable ICERs (compared to baseline) were ischemic heart disease mortality at its
lower bound (17% decrease) and cerebrovascular disease incidence and natural quit rates
when set at their upper bounds (12% and 7% decreases, respectively).When multiple
factors were considered (costs, utilities, incidence, and mortality for all smoking-related
diseases), changes in incremental cost-effectiveness ranged from cost-saving to 248%
beyond baseline. When all parameters were set at lower bounds, simulation yielded
smaller estimates. Participants in the original simulation yielded $32,842 in mean costs
versus $32,578 in the smoking simulation. Original and smoking simulations yielded 8.17
and 8.15 QALYs, respectively. Incremental cost-effectiveness was $13,200 per QALY
gained. At the upper bound of sensitivity analysis, costs increased to $64,150 and
$64,264 in original and smoking simulations. QALYs gained were higher, due to an
increased percentage of quitting over the lifetime (8.79 and 8.77 QALYs). In this case the
original simulation was cost-saving; successful quitters produced smaller mean costs.
Average age at death remained unchanged in sensitivity analysis. Disease cases averted
did change, however, ranging from an additional case of ischemic heart disease at lower
bounds to two cases of disease averted at upper bounds (one case each of cerebrovascular
disease and emphysema). Table 4-11 shows the impact of discounting on costeffectiveness estimates. Discount rates were adjusted in baseline analyses to five percent
and zero percent (undiscounted). Costs ranged from $41,920-$65,479 in the original
simulation and $41,863-$65,388 in the smoking simulations. Incremental costeffectiveness of successful quitting versus unsuccessful quitting ranged from $2,850$4,550 per QALY.
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Table 4-9. Comparisons of Original and All Smokers Simulations
Statistic
Cost
Effect
ACER
Cost difference
Effect difference
ICER
Quits at entry
Quit %, smokers
SR disease, n
IHD
CBD
LC
EMP
Age at death

Original
$49,025
8.62
$6,530
$69
0.02
$3,450
41
21.6%

All smokers
$48,956
8.6
$6,643
---0
16.9%

32
11
3
16
58.5

30
13
4
17
58.5

Note: Baseline simulations discounted at 3%. All costs are presented in year 2009 U.S.
dollars. Original simulation includes successful STEP study quitters. The ‘All smokers’
simulation assumes that all participants entered the model as smokers.
Abbreviations: ACER: average cost-effectiveness ratio, CBD: cerebrovascular disease,
EMP: emphysema, ICER: incremental cost-effectiveness ratio, IHD: ischemic heart
disease, LC: lung cancer, n: number, SR: smoking-related.
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Table 4-10. Sensitivity Analysis of Future Outcomes Simulations
Param L/H Statistic
Base
-Cost
QALY
NQ
L
Cost
Rate
QALY
H
Cost
QALY
QALY
IHD
L
Cost
inc
QALY
H
Cost
QALY
CBD L
Cost
inc
QALY
H
Cost
QALY
LC
L
Cost
inc
QALY
H
Cost
QALY
EMP L
Cost
inc
QALY
H
Cost
QALY
IHD
L
Cost
mort
QALY
H
Cost
QALY
CBD L
Cost
mort
QALY
H
Cost
QALY
LC
L
Cost
mort
QALY
H
Cost
QALY
EMP L
Cost
mort
QALY

O Sim
$49,025
8.62
$48,934
8.61
$49,166
8.64
8.79
$48,682
8.63
$49,179
8.62
$48,845
8.62
$49,114
8.62
$48,976
8.62
$49,075
8.62
$48,987
8.62
$48,975
8.62
$48,855
8.62
$49,195
8.62
$48,963
8.62
$49,087
8.62
$48,976
8.62
$49,073
8.62
$49,006
8.62

AS Sim
$48,956
8.6
$48,863
8.59
$49,100
8.62
8.78
$48,583
8.61
$49,096
8.6
$48,725
8.61
$49,053
8.6
$48,888
8.61
$49,006
8.6
$48,899
8.61
$48,884
8.61
$48,798
8.6
$49,115
8.61
$48,881
8.6
$49,031
8.61
$48,888
8.6
$49,024
8.61
$48,936
8.6
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IC
IE
$69 0.02

ICER Δ ICER
$3,450
--

%Δ
--

$71 0.02

$3,550

$100

3%

$66 0.02

$3,300

($150)

(4%)

$99 0.02

$4,950

$1,500

43%

$83 0.02

$4,150

$700

20%

$120 0.01 $12,000

$8,550

248%

$61 0.02

$3,050

($400)

(12%)

$88 0.01

$8,800

$5,350

155%

$69 0.02

$3,450

$0

0%

$88 0.01

$8,800

$5,350

155%

$91 0.01

$9,100

$5,650

164%

$57 0.02

$2,850

($600)

(17%)

$80 0.01

$8,000

$4,550

132%

$82 0.02

$4,100

$650

19%

$56 0.01

$5,600

$2,150

62%

$88 0.02

$4,400

$950

28%

$49 0.01

$4,900

$1,450

42%

$70 0.02

$3,500

$50

1%

Table 4-10. (continued)
Param L/H Statistic O Sim
H
Cost
$49,044
QALY
8.62
Costs L
Cost
$34,766
QALY
8.62
H
Cost
$63,283
QALY
8.62
Util
L
Cost
$49,025
QALY
8.45
H
Cost
$49,025
QALY
8.79
Inc
L
Cost
$48,537
(all)
QALY
8.63
H
Cost
$49,349
QALY
8.62
Mort L
Cost
$48,726
(all)
QALY
8.62
H
Cost
$49,324
QALY
8.63
All
L
Cost
$32,842
QALY
8.17
H
Cost
$64,150
QALY
8.79

AS Sim
IC
IE
ICER
Δ ICER
$48,976
$68 0.01 $6,800
$3,350
8.61
$34,492
$274 0.02 $13,700 $10,250
8.6
$63,420 ($137) 0.02
CS
-8.6
$48,956
$69 0.02 $3,450
$0
8.43
$48,956
$69 0.01 $6,900 $3,450
8.78
$48,422
$115 0.02 $5,750
$2,300
8.61
$49,283
$66 0.02 $3,300
($150)
8.6
$48,635
$91 0.02 $4,550
$1,100
8.6
$49,278
$46 0.02 $2,300 ($1,150)
8.61
$32,578
$264 0.02 $13,200
$9,750
8.15
$64,264 ($114) 0.02
CS
-8.77

%Δ
97%
297%
-0%
100%
67%
(4%)
32%
(33%)
283%
--

Note: Baseline simulations discounted at 3%. All costs are presented in year 2009 U.S.
dollars. Original simulation (O Sim) includes successful STEP study quitters. The ‘All
Smokers’ simulation (AS Sim) assumes that all participants entered the model as
smokers. Low and high parameters denote values for 95% confidence intervals.
Abbreviations: Δ: change in, %: percent, AS Sim: all smokers simulation, CBD:
cerebrovascular disease, CS: cost-saving, EMP: emphysema, H: high, IC: incremental
cost, IE: incremental effect, ICER: incremental cost-effectiveness ratio, IHD: ischemic
heart disease, L: low, LC: lung cancer, L/H: low/high, O Sim: original simulation, Param:
parameter, QALY: quality-adjusted life year, SR: smoking-related.
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Table 4-11. Sensitivity Analysis, Discount Rate

Statistic
Cost
Effect
ACE
Cost Diff
Eff Diff
ICER

Baseline
Original Smokers
$49,025 $48,956
8.62
8.60
$6,530
$6,643
$69
-0.02
-$3,450
--

Discount: 5%
Original Smokers
$41,920 $41,863
7.48
7.46
$6,473
$6,586
$57
-0.02
-$2,850
--

Undiscounted
Original Smokers
$65,479 $65,388
11.19
11.17
$6,624
$6,738
$91
-0.02
-$4,550
--

Note: Baseline simulations discounted at 3%. All costs are presented in year 2009 U.S.
dollars. Original simulation includes successful STEP study quitters. The ‘All smokers’
simulation assumes that all participants entered the model as smokers.
Abbreviations: ACE: average cost-effectiveness, Diff: difference, Eff: effect, ICER:
incremental cost-effectiveness ratio.
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Comparing STEP Cost-Effectiveness Analyses to the Literature
The league tables previously reported in Chapter 2 were updated to include results
of the current analyses. These results are reported in Table 4-12. STEP analysis is
reported at the end of all studies reporting costs per quit. This reflects stepped care as a
dominated strategy compared to repeat intervention. The long-term result is shown
among studies reporting cost per QALY. This result falls near the middle of all estimates.
Considering that STEP study participants received intervention as many as three times,
the incremental cost-effectiveness estimate for long-term intervention was expected to be
higher. However, at $3,450 per QALY, the Future Outcomes Simulation is highly costeffective.
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Table 4-12. Adjusted League Table, Cost-Effectiveness of Smoking Cessation
Interventions
Author

Intervention
Cost ($, 2009)
Cost/Quit
Hall et al.
MM + PI vs. MM alone
$545
Feenstra et al.
MC vs. current practice
$768
Hall et al.
MM + Nortrip vs. MM alone
$917
Hall et al.
MM + Bupr vs. MM alone
$1,868
Woolacott et al. Counsel + Bupr vs. counsel
$2,723
Feenstra et al.
TC vs. current practice
$2,798
Feenstra et al.
MC + NRT vs. current practice
$2,986
Woolacott et al. Counsel + NRT + Bupr vs. counsel
$3,795
Feenstra et al.
IC + Bupr vs. current practice
$4,112
Woolacott et al. Counsel + NRT vs. counsel
$4,264
Feenstra et al.
IC + NRT vs. current practice
$5,067
Barnett et al.
Stepped care vs. Brief intervention
$7,189
STEP Study
Stepped care vs. repeat intervention
Dominated
Cost/Quality-Adjusted Life-Year
Bolin et al.
Bupr vs. Patch (Males)
Bolin et al.
Bupr vs. Gum (Males)
Feenstra et al.
MC vs. current practice
Woolacott et al. Counsel + Bupr vs. counsel
Woolacott et al. Counsel + NRT + Bupr vs. counsel
Woolacott et al. Counsel + NRT vs. counsel
Feenstra et al.
TC vs. current practice
Feenstra et al.
MC + NRT vs. current practice
Bolin et al.
Bupr vs. Patch (Females)
STEP Study
Successful quitters vs. non-quitters
Bolin et al.
Bupr vs. Gum (Females)
Feenstra et al.
IC + Bupr vs. current practice
Feenstra et al.
IC + NRT vs. current practice

cost-saving
cost-saving
cost-saving
$1,008
$1,406
$1,579
$1,877-$2,559
$2,389-$2,900
$2,539
$3,450
$4,054
$5,801-$6,142
$8,360-$8,872

Note: STEP Study intervention denoted in italics.
Abbreviations: Bupr: bupropion; IC: intensive counseling; MC: minimal counseling;
MM: medical management; Nortrip: nortriptyline; NRT: nicotine replacement therapy;
PI: psychological intervention; TC: telephone counseling.
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CHAPTER 5: CONCLUSIONS
Discussion
This study sought to evaluate the use of stepped care in smoking cessation
interventions to increase cessation among smokers ready to quit. When compared to a
repeated therapy intervention, stepped care did not prove cost-effective. Stepped care
produced a greater percentage of continuous quitters only among women in the Mayo
Clinic sample; this was the only scenario in which the ICER fell within estimates
reported in the literature review in Chapter 2. Cessation rates favored stepped care in UT
women, Mayo men, and the overall Mayo sample, but none of the differences observed
were statistically significant. Thus, ICERs produced in these subgroups fell beyond the
threshold of $10,000 per quit. However, when comparing alternatives that are considered
equally efficacious, the general rule is to choose the strategy with the lower cost. In the
case of STEP, repeat care dominated stepped care, as it was less costly and equally
effective. As such, it would not be wise to recommend stepped care over repeated
intervention.
While stepped care was not proven cost effective, both study arms produced
significant rates of continuous abstinence at two years. These rates, for both continuous
and point-prevalence abstinence, are in line with results reported in short-term studies
reviewed. Many of the short-term studies evaluated outcomes at one year or 18 months;
STEP results are comparable at 24 months. This study fills a large gap in the literature
regarding rates of long-term abstinence after cessation intervention. The benefits seen
with repeat care affirm newer findings by Fu and Han.105, 106 Fu and colleagues evaluated
a sample of Veterans Affairs (VA) patients who had relapsed at six months post-tobacco
cessation treatment, demonstrating that nearly two-thirds were interesting in recycling.
The researchers also inquired about the type of treatment the smokers were interested in
using; the majority were interested in combination pharmacotherapy and behavioral
counsel.102 Han and colleagues examined a subset of patients who returned to a tobacco
dependence clinic to receive repeat treatment(s) following initial relapse. Subsequent quit
attempts by repeaters were similar to abstinence rates achieved in a larger sample
receiving intervention once.106
Several differences were noted among participants across study sites, race, and
gender. First, participation rates were quite different across sites, with nearly three-fold
greater attendance at all visits among UTHSC versus Mayo participants. Unfortunately,
increased participation did not impact quitting. CES-D scores were higher among
UTHSC versus Mayo Clinic, and specifically in the stepped care arm. This could have
likely influenced lower levels of quitting at the UTHSC site. Differences in efficacy
observed across race and gender also require further discussion. Non-Hispanic whites
achieved higher rates of cessation versus ethnic minorities, as did men (versus women).
A variety of factors may have contributed to these differences, but that discussion extends
beyond the scope of this analysis. The low rates achieved by ethnic minorities are
concerning, suggesting that neither repeated nor stepped care was beneficial for achieving
cessation. In fact, the continuous abstinence rate observed in ethnic minorities was
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similar to one reported by Hughes which was based on self-quitting. That such a
significant portion of minorities participated in the study is moderately encouraging;
however, the results are still disappointing. Data affirm that success rates among ethnic
minorities are generally lower, despite making as many or more quit attempts compared
to white smokers.107-109 Qualitative studies, specifically those addressing barriers to
treatment delivery, use, or success, might play a significant role in informing future
research in this population.33, 109
The results of the future outcomes simulation were very positive. Study
intervention produced a cost-effectiveness estimate that was extremely cost-effective
when compared to other studies in the literature. Average age at death in the original
simulation was no higher than in the smoking simulation; smoking cessation did not
impact age at death, but did impact cause. Ultimately, participants in whom smokingrelated disease was averted died from other causes. In sensitivity analysis, costeffectiveness remained favorable, but benefits of cessation related to disease incidence
were lost, especially when disease incidence decreased or more smokers quit on their
own. Successful smoking cessation impacted incidence of emphysema, lung cancer, and
cerebrovascular disease, but not ischemic heart disease. This is likely due to the fact that
smoking is only attributable to one-fifth of ischemic heart disease incidence.10 Overall,
the impact of decreased smoking-related disease incidence yielded an attractive estimate
of incremental cost-effectiveness. Results of the future outcomes simulations demonstrate
the importance and economic feasibility of investing in smoking cessation, even in small
populations.
Strengths
This study has a number of strengths. First, the underlying study is comprised of a
diverse mix of smokers, especially those of ethnic minority or low income populations.
As mentioned previously, these are two smoking groups that have been challenged with
disparate access to therapy and ultimately difficulties with successful cessation. The
literature evaluating smoking cessation interventions among these two key groups is still
sparse. This study confirms that continued research is warranted to address tobacco
dependence among ethnic minorities. Also, using the assumption of smoking for patients
missing the final visit likely provides a conservative estimate of efficacy and costeffectiveness. This strategy is generally employed in smoking cessation studies for
persons lost to follow-up.
In terms of the simulation of future outcomes, the data sources utilized were
relatively new, using the most recent year(s) available. Moreover, these data are
nationally representative, providing reliable estimates of disease incidence, mortality risk,
healthcare costs and utilities across age, race, and gender. In addition, the model
constructed for simulation of future health outcomes was derived from various models
which have been widely used in the literature.94, 95 It accounts for a wider variety of
tobacco-related diseases than earlier single-disease models. However, it is not as complex
as a newer cessation model, which encompasses 14 tobacco-related diseases.85 Given the
uncertainty about the disease pathways that smokers follow after cessation, only more
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common smoking-related diseases were captured. Because of this, long-term costeffectiveness analysis likely underestimates the economic benefits of quitting. Further,
the model did not account for productivity gains associated with smoking cessation or
gains associated with reallocation of resources used to purchase tobacco products. Other
economic impacts of smoking cessation on society are also ignored. For example,
smoking cessation reduces involuntary exposure to tobacco smoke, potentially averting
cases of illness caused by secondhand smoke.
Limitations
Results of the cost-effectiveness analysis of stepped care versus repeat care must
be interpreted with caution. It must be noted that UTHSC patients in the analysis sample
reported higher CES-D scores and baseline carbon monoxide readings than the remaining
group. The extent to which these variables might influence other outcomes is unknown.
Moreover, the study was not powered to detect significant differences in costeffectiveness. Especially among joint clinical/economic studies, underlying studies may
be adequately powered for clinical outcomes, but inadequately powered for economic
outcomes.110 To achieve joint power, much larger sample sizes are required; this
introduces potential ethical and practical issues.111 Several methods have been put
forward to power studies for economic outcomes, but these techniques have not yet been
widely employed in cost-effectiveness analyses.112-117 The current study utilized
confidence interval estimation to characterize uncertainty around cost-effectiveness
estimates; this technique is a generally accepted alternative to hypothesis testing or power
calculations.118-121
Next, the extent to which the demographic profile of STEP participants resembles
the current smoking population in the United States will impact the generalizability of
results to a larger group. A key limitation here is related to the absence of certain special
populations of smokers in the study, including those who were pregnant, had psychiatric
comorbidities or other medical conditions deemed ineligible for inclusion. Smoking
cessation interventions containing pharmacotherapy have not yet been deemed
appropriate for pregnant smokers; as such, no statement regarding cost-effectiveness of
this particular stepped care intervention can be made for them. In addition, results cannot
be extended to other key smoking populations not represented in the STEP study.
Another limiting factor in this analysis is related to the study setting. Study participants,
though diverse, may not be representative of the larger smoking population, as their
interest in participating in STEP may differentiate them from other smokers. Receipt of
free medication and compensation for time may have impacted participation throughout
the study. As such, the outcomes observed in STEP may not be reflected in natural
settings. Finally, the reliability of the results obtained in the simulation wholly depends
on the accuracy of assumptions made in structure of and data used in the model.
In the long-term model evaluating future outcomes of smoking cessation, utilities
were derived using a mapping algorithm from Sullivan. Other algorithms have been used
similarly to map between SF-12 and EQ-5D scores, including one by Brazier.122 Use of
mapping techniques may not accurately reflect utilities among this or a community-based
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population. Another issue to consider in use of HRQL scores is the ensuing debate
regarding racial/ethnic differences in valuation and its impact on cost-effectiveness
research. Wang, Saalfrank, and Gaskin have demonstrated through literature review and
other analysis that racial and ethnic differences do exist.123-125 Further, they emphasize a
need for research to explore factors influencing these differences and to use caution when
applying health-related quality of life across diverse populations in cost-utility analysis.
For this reason, utilities used in the model were not adjusted for race/ethnicity to avoid
biases in the cost-effectiveness measures.
Promoting Smoking Cessation in Primary Care
Greater efforts are needed for integrating smoking cessation treatment into
primary care practice. The primary care setting is considered the most appropriate for
addressing tobacco dependence; opportunities exist for repeated intervention by
physicians, nurses, pharmacists, and dentists, among others. However, provision of
support for smoking cessation has not been a priority for general clinicians, as evidenced
in a recent report. An analysis conducted by Maciosek and colleagues revealed
significant underutilization of preventive services for smoking cessation.126 Using 2005
HEDIS data, the researchers found that 48% of smokers received advice to quit from
physicians, while only 28% of smokers reported receiving medical assistance to quit.
They surmised that if the percentage offered assistance were increased to 90%, an
additional 42,000 lives might be saved. Similar inconsistencies in intervention among
providers have been documented in the Guidelines and other literature.
The design of the STEP study provides a feasible model for smoking cessation
intervention in the primary care setting. Research indicates that smokers make more
visits per year to a physician than non-smokers.11 These primary care visits could serve as
treatment visits, in which physicians or nurses could assess smoking status, gauge
readiness and commitment to quit, provide counseling and/or pharmacotherapy, and
schedule follow-up. Telephone follow-up could be conducted by a nurse or staff person
to provide support until the next visit. At subsequent visits, quit status could be assessed
and repeated intervention employed if necessary until a quit is achieved. Provision of
continuous intervention is key; it has been shown to increase cessation nearly four-fold
when compared to one-time intervention.127 Follow-up through and beyond 12 months
post-cessation is equally critical for ensuring long-term success.
Economic Evaluation for Healthcare Financing
In many countries, the formal use of economic evaluation is mandated to guide
healthcare financing (including coverage of healthcare medications and treatments).
Since 1992, Australia, Canada, Portugal, Finland, and the Netherlands have formalized
and issued guidelines on the systematic use of economic evaluation in healthcare policy
and decision making. More recently, the United Kingdom established an independent
organization, National Institute for Health and Clinical Excellence (NICE), to provide
clinical and economic guidance in public health, health technologies, and clinical
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practice. In other European countries, informal guidelines have been established to
achieve these aims. In the United States, informal guidelines or recommendations have
been published, but their use is not enforced. As such, Gold and colleagues emphasize a
need for standardization, due to the increased use of economic data in guiding allocation
of healthcare resources.
While growth of economic evaluation in healthcare decision-making is
acknowledged, it has yet to be wholly embraced as a systematic tool for justifying
healthcare financing. Given the extent to which cost-effectiveness drives approval of new
medicines in the United Kingdom, researchers there assert that even where the best
possible economic evaluations are available, they are only one element in a complex
process of decision-making that is also shaped by what is politically feasible. In the
United States, Williams and colleagues highlight two key barriers to the use of economic
analyses in healthcare—accessibility and acceptability of research evidence.128
Difficulties in interpretation of data (due to lack of statistical expertise) and presentation
of results hamper the accessibility of economic evaluation for decision-making. In
addition, acceptance of economic evaluation hinges on decision-makers’ perception of its
relevance in addressing emerging health needs. A focus group study evaluating
usefulness of economic evaluations found that decision makers valued information on
cost-effectiveness, but suggested methodological improvements to increase the reliability
of economic studies.129 A small body of literature has surfaced in the last decade, which
promotes incorporating the scientific rigors of clinical studies into economic evaluations.
Several researchers have proposed the adoption of hypothesis testing and put forth
various methods for constructing confidence intervals and performing sample size and
power calculations.113, 115-117 In Europe, the generalized cost-effectiveness analysis has
been developed to address shortcomings of previous economic evaluations.
Gold and colleagues assert that improvements in the standardization of costeffectiveness analysis methods will allow progress toward more systematic use of CEA in
policy- and decision-making, especially for the United States. In the meantime, the health
system will continue to use other implicit or explicit means to allocate limited resources.
Whether through formal means of cost-effectiveness analysis or otherwise, healthcare
payers in the U.S. are using clinical and economic evidence in their considerations of
coverage of tobacco cessation pharmacotherapies and related programs. Phillips-Tangum
and colleagues have studied trends in health plan coverage of smoking cessation
therapies; their recent analysis found that coverage for any tobacco dependence treatment
increased from 25 percent of health plans in 1997 to 88 percent of health plans in 2003,
the most recent year data were available.130 The authors attributed this increase in
coverage to the growing body of literature indicating that reducing treatment costs is
associated with greater use of tobacco cessation programs and services, which can
increase rates of cessation.
Medicaid is one payer that has given particular attention to the economic benefits
of smoking cessation treatment coverage. Whereas smokers comprise one-fifth of the
general population, one-third of Medicaid enrollees are current smokers. Medicaid
coverage of smoking cessation therapies and counseling increased substantially from
2002-2006.131 At the end of 2002, 36 Medicaid programs covered some tobacco71

dependence counseling or medication for all Medicaid recipients, four states offered
coverage only for pregnant women, two states offered coverage for all pharmacotherapy
and counseling treatments recommended by the 2000 PHS guideline, and seven states
covered all recommended medications and at least one form of counseling. By 2006, 39
state Medicaid programs (including the District of Columbia) covered some form of
tobacco-dependence treatment (i.e., medication or counseling) for all Medicaid recipients
and one state program provided coverage for all recommended treatments. Two states
that previously provided no coverage for tobacco-dependence treatment began coverage
in 2006. In addition, 32 states added coverage for varenicline (Chantix™ [Pfizer,
Mission, Kansas]), one state expanded its coverage to include the nicotine lozenge, and
one state expanded coverage to include individual counseling.131
Despite inherent limitations of economic evaluation as a complete tool for
healthcare decision-making, the overwhelming affirmation of the cost-effectiveness of
smoking cessation therapies indicates that any future economic evaluations will continue
to influence (formally or informally) greater coverage of pharmacotherapies and adoption
of novel interventions and programs to promote cessation efforts. A new report by the
Pacific Center on Health and Tobacco has proposed integrating telephone quitlines into
healthcare systems.132 The need for referrals among quitlines and referral sources among
healthcare systems creates a unique opportunity for partnership. The report documented
initiatives taken by several states to develop enhanced smoking cessation service
networks. Smoking cessation is also a key focus in the healthcare platform of the current
presidential administration; economic stimulus bills presented to Congress have included
over $75 million for funding smoking cessation campaigns and purchasing equipment for
smoking research.
Future Directions
Newer tobacco control initiatives targeting current smokers are increasingly
focused on technology-based methods for increasing cessation. Given the popularity of
the iPhone™ [Apple, Inc.], the National Tobacco Cessation Collaborative (NTCC) and
George Washington University School of Public Health and Health Services have
developed an application, “My Quitline”, to help smokers quit. The free application, once
downloaded, will place users in direct contact with National Cancer Institute’s quitline
counselors via phone or text. Mobile-phone based programs in the U.S. have targeted
young adults, particularly college students, with some success.133, 134 Bock and her
colleagues, in 2008, updated a previous review of the quality of web-assisted tobacco
interventions (WATIs).135 Their search yielded over 80 websites claiming to offer U.S.
smokers assistance with quitting smoking, but only one-fourth of these met Guidelines
criteria. The excluded websites sold smoking-cessation programs rather than providing
support for smokers wanting to quit. Their findings, however, did suggest improvement
in quality of websites in providing advice to quit, offering practical counseling, and
enhancing motivation to quit. The researchers proposed further research on maximizing
interactive capabilities (personalizing treatment, providing a virtual support system,
facilitating follow-up) of smoking cessation websites to improve outcomes.135 While
technology-based methods are promising, their success depends on their ability to affect
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the remaining smoking population. Telephone quitlines have improved in this regard,
with a new study showing increased reach among ethnic minorities as well as older, less
educated, heavier smokers.57
Conclusions
Stepped care cannot be dismissed yet as a viable method for improving smoking
cessation rates. In the most recent update of the Guidelines, both the inconsistency of
results and overall paucity of literature kept panel members from recommending stepped
care or tailored methods for smoking cessation. Since the update, two other studies have
evaluated the use of stepped therapy in a smoking cessation intervention and reported
positive results. Christenhusz et al evaluated use of stepped care intervention in smokers
with moderate to severe COPD.136 Usual care participants received a brief counseling
intervention with an opportunity to receive pharmacotherapy at cost; stepped care
participants received individual and group counseling and bupropion. If stepped care
patients lapsed within three months, additional counseling was provided. Usual care
participants received no further intervention. Ultimately, higher rates of continuous
abstinence at one year for stepped care versus usual care (19% versus 9%) were reported.
Further, logistic regression results found no baseline characteristics (i.e. attitude toward
quitting, baseline cotinine value) to significantly predict cessation in the stepped care
arm, indicating that less-motivated smokers could benefit from intensive stepped care
therapy. Barnett et al applied a stepped care intervention to smokers in a mental health
setting.77 Usual care participants received brief counsel and a list of available smoking
cessation services. Stepped care patients received up to three assessments of readiness to
quit, with contemplators or requestors receiving 10 weeks of NRT therapy and
counseling. Upon relapse, additional counseling was provided. At 18-month follow-up,
24.6% of stepped care patients versus 19.1% of usual care patients achieved pointprevalent cessation. Incremental cost-effectiveness of stepped care was $6,204 per quit. A
large-scale study of stepped care (n= 3,024) has been conducted in Spain; the results have
not yet been reported.137
Future studies of stepped care in smoking cessation will need to provide solid
evidence of its effectiveness before any formal recommendation can be made. Particular
emphasis should be placed on development of standardized study protocols. Published
studies evaluating stepped care have lacked agreement on decision criteria for
implementing subsequent steps for stepped care interventions. Four studies used relapse
as the determinant for intensifying therapy,74, 77, 136, 138 while the remainder used looser
criteria for initiating subsequent steps.75, 139 Additionally, one study attributed poor results
to inconsistency of staff follow-up.136 Research investigating optimal timing and content
of interventions is also warranted; Smith and Reid mentioned these as contributors to
poor study outcomes.74, 75 If stepped care in smoking cessation is to become viable,
researchers will need to explore and implement factors that have influenced its success in
treatment of other various chronic diseases, especially substance abuse disorders.
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